

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/21, 9/88, 15/63, 15/60, 15/09, 15/67, 15/70		A1	(11) International Publication Number: WO 95/34635 (43) International Publication Date: 21 December 1995 (21.12.95)
(21) International Application Number: PCT/US95/07391 (22) International Filing Date: 9 June 1995 (09.06.95)		(81) Designated States: AU, BR, CA, CN, FI, HU, JP, KR, NO, NZ, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/258,639 10 June 1994 (10.06.94) US		Published <i>With international search report.</i>	
(71) Applicant: IBEX TECHNOLOGIES [CA/CA]; 5485 Paré, Montréal, Québec H4P 1P7 (CA).			
(71)(72) Applicant and Inventor: ZIMMERMANN, Joseph [US/US]; 13450 Nicolet Avenue, Elm Grove, WI 53122 (US).			
(72) Inventors: SU, Hongsheng; 2998 Baritean, Lonquenil, Québec J4M 2R7 (CA). BLAIN, Françoise; 2635 Rufus, Rockhead #B204, Montréal, Québec H3J 2W6 (CA). BENNETT, Clark; 4965 Hortie, Pierrefonds, Québec H8Y 1Z4 (CA). GU, Kangfu; 106 Viking Place, D.D.O., Québec H9G 2P1 (CA). MUSIL, Roy; 2349 D Altisma Way, Carlsbad, CA 92009 (US).			
(74) Agents: BAKER, Hollie, L. et al.; Hale and Dorr, 1455 Pennsylvania Avenue, N.W., Washington, DC 20004 (US).			
(54) Title: NUCLEIC ACID SEQUENCES AND EXPRESSION SYSTEMS FOR HEPARINASE II AND HEPARINASE III DERIVED FROM FLAVOBACTERIUM HEPARINUM			
(57) Abstract			
<p>The present invention describes the isolation and sequence of genes from <i>Flavobacterium heparinum</i> encoding heparin and heparan sulfate degrading enzymes, heparinase II and heparinase III (EC 4.2.2.8). It further describes a method of expressing and an expression for heparinases I, II and III using a modified ribosome binding region derived from a promoter from glycosaminoglycan lyase genes of <i>F. heparinum</i>. Also, a multi-step protein purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography is outlined. Antibodies against a post-translational modification moiety common to <i>Flavobacterium heparinum</i> proteins and a method to obtain antibodies specific to these moieties and to the amino acid sequences of heparinases I, II and III are described.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**NUCLEIC ACID SEQUENCES AND EXPRESSION SYSTEMS FOR
HEPARINASE II AND HEPARINASE III
DERIVED FROM *Flavobacterium heparinum***

5

BACKGROUND OF THE INVENTION

This invention is directed to cloning, sequencing and expressing heparinase II and heparinase III from *Flavobacterium heparinum*.

The heparin and heparan sulfate family of molecules is comprised of glycosaminoglycans of repeating glucosamine and hexuronic acid residues, either iduronic or glucuronic, in which the 2, 3 or 6 position of glucosamine or the 2 position of the hexuronic acid may be sulfated. Variations in the extent and location of sulfation as well as conformation of the alternating hexuronic acid residue leads to a high degree of heterogeneity of the molecules within this family. Conventionally, heparin refers to molecules which possess a high sulfate content, 2.6 sulfates per disaccharide, and a higher amount of iduronic acid. Conversely, heparan sulfate contains lower amounts of sulfate, 0.7 to 1.3 sulfates per disaccharide, and less iduronic acid. However, variants of intermediate composition exist and heparins from all biological sources have not yet been characterized.

Specific sulfation/glycosylation patterns of heparin have been associated with biological function, such as the antithrombin binding site described by Choay *et al.*, *Thrombosis Res.* 18: 573-578 (1980), and the fibroblast growth factor binding site described by Turnbull *et al.*, *J. Biol. Chem.* 267: 10337-10341 (1992). It is apparent from these examples that heparin's interaction with certain molecules results from the conformation imparted by specific sequences and not solely due to electrostatic interactions imparted by its high sulfate composition. Heparin interacts with a variety of mammalian molecules, thereby modulating several

biological events such as hemostasis, cell proliferation, migration and adhesion as summarized by Kjellen and Lindahl, *Ann Rev Biochem* 60: 443-475 (1991) and Burgess and Macaig, *Ann. Rev. Biochem.* 58: 575-606 (1989). Heparin, extracted from bovine lungs and porcine intestines, has been used as an anticoagulant since its antithrombotic properties were discovered by McLean, *Am. J. Physiol.* 41: 250-257 (1916). Heparin and chemically modified heparins are continually under review for medical applications in the areas of wound healing and treating vascular disease.

Heparin degrading enzymes, referred to as heparinases or heparin lyases, have been identified in several microorganisms including: *Flavobacterium heparinum*, *Bacteroides* sp. and *Aspergillus nidulans* as summarized by Linhardt *et al.*, *Appl. Biochem. Biotechnol.* 12: 135-177 (1986). Heparan sulfate degrading enzymes, referred to as heparitinases or heparan sulfate lyases, have been detected in platelets (Oldberg *et al.*, *Biochemistry* 19: 5755-5762 (1980)), tumor (Nakajima *et al.*, *J. Biol. Chem.* 259: 2283-2290 (1984)) and endothelial cells (Gaal *et al.*, *Biochem. Biophys. Res. Comm.* 161: 604-614 (1989)). Mammalian heparanases catalyze the hydrolysis of the carbohydrate backbone of heparan sulfate at the hexuronic acid (1 → 4) glucosamine linkage (Nakajima *et al.*, *J. Cell. Biochem.* 36: 157-167 (1988)) and are inhibited by the highly sulfated heparin. However, accurate biochemical characterizations of these enzymes has thus far been prevented by the lack of a method to obtain homogeneous preparations of the molecules.

Flavobacterium heparinum produces heparin and heparan sulfate degrading enzymes termed heparinase I (E.C. 4.2.2.7) as described by Yang *et al.*, *J. Biol. Chem.* 260(3): 1849-1857 (1985), heparinase II as described by Zimmermann and Cooney, U.S. Patent No. 5,169,772, and heparinase III (E.C. 4.2.2.8) as described by Lohse and Linhardt, *J. Biol. Chem.* 267: 24347-

24355 (1992). These enzymes catalyze an eliminative cleavage of the ($\alpha 1 \rightarrow 4$) carbohydrate bond between glucosamine and hexuronic acid residues in the heparin/heparan sulfate backbone. The three enzyme variants differ in their action on specific carbohydrate residues.

5 Heparinase I cleaves at α -D-GlcNp2S6S($1 \rightarrow 4$) α -L-IdoAp2S, heparinase III at α -D-GlcNp2Ac(or2S)6OH($1 \rightarrow 4$) β -D-GlcAp and heparinase II at either linkage as described by Desai *et al.*, *Arch. Biochem. Biophys.* 306(2): 461-468 (1993). Secondary cleavage sites for each enzyme also have been described by Desai *et al.*

10 Heparinase I has been used clinically to neutralize the anticoagulant properties of heparin as summarized by Baugh and Zimmermann, *Perfusion Rev.* 1(2): 8-13, 1993. Heparinase I and III have been shown to modulate cell-growth factor interactions as demonstrated by Bashkin *et al.*, *J. Cell Physiol.* 151:126-137 (1992) and 15 cell-lipoprotein interactions as demonstrated by Chappell *et al.*, *J. Biol. Chem.* 268(19):14168-14175 (1993). The availability of heparin degrading enzymes of sufficient purity and quantity could lead to the development of important diagnostic and therapeutic formulations.

20

SUMMARY OF THE INVENTION

Prior to the present invention, partially purified heparinases II and III were available, but their amino acid sequences were unknown. Cloning these enzymes was difficult because of toxicity to the host cells. The present inventors were able to clone the genes for heparinases II and III, and herein provide their nucleotide and amino acid sequences.

25 A method is described for the isolation of highly purified heparin and heparan sulfate degrading enzymes from *F. heparinum*.

Characterization of each protein demonstrated that heparinases I, II and III are glycoproteins. All three proteins are modified at their N-terminal amino acid residue. Antibodies generated by injecting purified heparinases into rabbits yielded anti-sera which demonstrated a high degree of cross reactivity to proteins from *F. heparinum*. Polyclonal antibodies were separated by affinity chromatography into fractions which bind the amino acid portion of the proteins and a fraction which binds the post-translational modification allowing for the use of these antibodies to specifically distinguish the native and recombinant forms of each heparinase protein.

Amino acid sequence information was used to synthesize oligonucleotides that were subsequently used in a polymerase chain reaction (PCR) to amplify a portion of the heparinase II and heparinase III genes. Amplified regions were used in an attempt to identify clones from a λDASH-II gene library which contained *F. heparinum* genomic DNA. Natural selection against clones containing the entire heparinase II and III genes was observed. This was circumvented by cloning sections of the heparinase II gene separately, and by screening host strains for stable maintenance of complete heparinase III clones. Expression of heparinase II and III was achieved by use of a vector containing a modified ribosome binding site which was shown to increase the expression of heparinase I to significant levels.

This patent describes the gene and amino acid sequences for heparinase II and III from *F. heparinum*, which may be used in conjunction with suitable expression systems to produce the enzymes. Also described, is a modified ribosome binding sequence used to express heparinase I, II, and III.

SUBSTITUTE SHEET (RULE 26)

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the modifications to the tac promoter ribosome binding region, which were evaluated for the level of expression of heparinase I. The original sequence, as found in pBhep, and the modified sequences, as found in pGhep and pΔ4hep, are shown with the Shine-Dalgarno sequences (S-D) and the heparinase I gene start codon, underlined. The gap (in nucleotides, nt) between these regions is indicated below each sequence. The ribosome binding region for pGB contains no start codon, and has a *BamHI* site (underlined) in place of the *EcoRI* site (GAATTC) found in pGhep.

Figure 2 shows the construction of plasmids used to sequence the heparinase II gene from *Flavobacterium heparinum*. Restriction sites are: N-*NotI*, Nc = *NcoI*, S = *SalI*, B = *BamHI*, P = *PstI*, E = *EcoRI*, H = *HindIII*, C = *Clal* and K = *KpnI*.

Figure 3 shows the construction of pGBH2, a plasmid capable of directing the expression of active heparinase II in *E. coli* from tandem tac promoters (double arrow heads). Restriction sites are: B = *BamHI*, P = *PstI*.

Figure 4 shows the nucleic acid sequence for the heparinase II gene from *Flavobacterium heparinum* (SEQU ID NO:1).

Figure 5 shows the amino acid sequence for heparinase II from *Flavobacterium heparinum* (SEQU ID NO:2). The leader peptide sequence is underlined. The mature protein starts at Q-26. Peptides 2A, 2B and 2C are indicated at their corresponding positions within the protein.

Figure 6 shows the construction of plasmids used to sequence the heparinase III gene from *Flavobacterium heparinum*. Restriction sites are: S = *SalI*, B = *BamHI*, P = *PstI*, E = *EcoRI*, H = *HindIII*, C = *Clal* and K = *KpnI*.

Figure 7 shows the construction of pGBH3, a plasmid capable of directing the expression of active heparinase III in *E. coli* from a tandem *taq* promoter (double arrow heads). Restriction sites are: S = *Sal*I, B = *Bam*HI, P = *Pst*I, E = *Eco*RI, H = *Hind*III, Bs = *Bsp*EI, C = *Cla*I and K = *Kpn*I.

5 Figure 8 shows the nucleic acid sequence for the heparinase III gene from *Flavobacterium heparinum* (SEQU ID NO:3).

Figure 9 shows the amino acid sequence for heparinase III from *Flavobacterium heparinum* (SEQU ID NO:4). The leader peptide sequence is underlined. The mature protein starts at Q-25. Peptides 3A, 3B and 3C are 10 indicated at their corresponding positions within the protein.

DETAILED DESCRIPTION OF THE INVENTION

To aid in the understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

15 Gene. By the term "gene" is intended a DNA sequence which encodes through its template or messenger RNA a sequence of amino acids characteristic of a specific peptide. Further, the term includes intervening, non-coding regions, as well as regulatory regions, and can include 5' and 3' ends.

20 Gene sequence. The term "gene sequence" is intended to refer generally to a DNA molecule which contains one or more genes, or gene fragments, as well as a DNA molecule which contains a non-transcribed or non-translated sequence. The term is further intended to include any combination of gene(s), gene fragments(s), non-transcribed sequence(s) or 25 non-translated sequence(s) which are present on the same DNA molecule.

The present sequences may be derived from a variety of sources including DNA, synthetic DNA, RNA, or combinations thereof. Such gene sequences may comprise genomic DNA which may or may not include

naturally occurring introns. moreover, such genomic DNA may be obtained in association with promoter regions or poly A sequences. The gene sequences, genomic DNA or cDNA may be obtained in any of several ways.

Genomic DNA can be extracted and purified from suitable cells, such as
5 brain cells, by means well known in the art. Alternatively, mRNA can be isolated from a cell and used to produce cDNA by reverse transcription or other means.

10 Recombinant DNA. By the term "recombinant DNA" is meant a molecule that has been recombined by *in vitro* splicing cDNA or a genomic DNA sequence.

15 Cloning Vehicle. A plasmid or phage DNA or other DNA sequence which is able to replicate in a host cell. The cloning vehicle is characterized by one or more endonuclease recognition sites at which DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the DNA, which may contain a marker suitable for use in the identification of transformed cells. Markers include for example, tetracycline resistance or ampicillin resistance. The word vector can be used to connote a cloning vehicle.

20 Expression Control Sequence. A sequence of nucleotides that controls or regulates expression of structural genes when operably linked to those genes. They include the *lac* systems, the *trp* system major operator and promoter regions of the phage lambda, the control region of fd coat protein and other sequences known to control the expression of genes in prokaryotic or eukaryotic cells.

25 Expression vehicle. A vehicle or vector similar to a cloning vehicle but which is capable of expressing a gene which has been cloned into it, after transformation into a host. The cloned gene is usually placed under the control of (i.e., operable linked to) certain control sequences such as

promoter sequences. Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host and may additionally contain transcriptional elements such as enhancer elements, termination 5 sequences, tissue-specificity elements, and/or translational initiation and termination sites.

Promoter. The term "promoter" is intended to refer to a DNA sequence which can be recognized by an RNA polymerase. The presence of such a sequence permits the RNA polymerase to bind and initiate 10 transcription of operably linked gene sequences.

Promoter region. The term "promoter region" is intended to broadly include both the promoter sequence as well as gene sequences which may be necessary for the initiation of transcription. The presence of a promoter region is, therefore, sufficient to cause the expression of an operably linked 15 gene sequence.

Operably Linked. As used herein, the term "operably linked" means that the promoter controls the initiation of expression of the gene. A promoter is operably linked to a sequence of proximal DNA if upon introduction into a host cell the promoter determines the transcription of 20 the proximal DNA sequence or sequences into one or more species of RNA. A promoter is operably linked to a DNA sequence if the promoter is capable if initiating transcription of that DNA sequence.

Prokaryote. The term "prokaryote" is meant to include all organisms without a true nucleus, including bacteria.

Host. The term "host" is meant to include not only prokaryotes, but also such eukaryotes as yeast and filamentous fungi, as well as plant and animal cells. The terms includes organisms or cell that is the recipient of a replicable expression vehicle.

The present invention is based on the cloning and expression of two previously uncloned enzymes. Although heparinases II and III had been partially purified previously, no amino acid sequences were available. Specifically, the invention discloses the cloning, sequencing and expression 5 of heparinases II and III from *Flavobacterium heparinum* and the use of a modified ribosome binding region for expression of these genes. In addition to the nucleotide sequences, the amino acid sequences of heparinases II and II are also provided. The invention further provides expressed heparinases I, II and III, as well as methods of expressing those 10 enzymes.

Cloning was accomplished using degenerate and "guessmer" nucleotide primers derived from amino acid sequences of fragments of the heparinases, purified as described below in detail. The amino acid sequences were previously unavailable. Cloning was exceptionally difficult 15 because of the unexpected problem of *F. heparinum* DNA toxicity in *E. coli*. The inventors discovered techniques for solving this problem, as described below in detail. Based on this disclosure, one skilled in the art can readily clone additional heparinases and other proteins from *F. heparinum* or from additional sources using the novel methods described within.

20 Expression of the heparinases is a further disclosure of the present invention. To express heparinases I, II and III, transcriptional and translational signals recognizable by an appropriate host are necessary. The cloned heparinases encoding sequences, obtained through the methods described above, and preferably in a double-stranded form, may be 25 operably linked to sequences controlling transcriptional expression in an expression vector, and introduced into a host cell, either prokaryote or eukaryote, to produce recombinant heparinases or a functional derivative thereof. Depending upon which strand of the heparinases encoding

sequence is operably linked to the sequences controlling transcriptional expression, it is also possible to express heparinases antisense RNA or a functional derivative thereof.

For the expression of heparinases I, II and III in *E. coli*, vectors were constructed wherein expression was driven by two repeats of the tac promoter. Modifications of the ribosome binding region of this promoter were made by introducing mutations with the polymerase chain reaction. In a preferred modification of the expression vector, the minimal consensus Shine-Delgarno sequence was improved by introducing a single mutation (AGGAA → AGGAG), which had the further advantage of decreasing the number of nucleotides between the Shine-Delgarno sequence and the ATG start codon. Further modifications were produced using PCR in which the gap between the Shine-Delgarno sequence and the start codon were further reduced. Using the same techniques, additional modifications in this region, including insertions and deletions, can be produced to create additional heparinase expression vectors. As a result, an expression vector for the expression of heparinases is provided which comprises a modified ribosome binding region containing a 5 base pair Shine-Dalgarno sequence, a 9 base pair spacer region between the Shine-Dalgarno sequence and the ATG start codon, and a recombinant nucleotide sequence encoding. Also provided are modifications to this vector comprising changing the length and sequence of the Shine-Dalgarno sequence, and also by reducing the spacing between the Shine-Dalgarno sequence and the start codon to 8, 7, 6, 5, 4 or fewer nucleotides. Methods of expressing the heparinases using these novel expression vectors comprise a preferred embodiment of the invention.

Expression of the heparinases in different hosts may result in different post-translational modifications which may alter the properties

of the heparinases, or a functional derivative thereof, in eukaryotic cells, and especially mammalian, insect and yeast cells. Especially preferred eukaryotic hosts are mammalian cells either *in vivo*, in animals or in tissue culture. Mammalian cells provide post-translational modifications to recombinant heparinases which include folding and/or glycosylation at sites similar or identical to that found for the native heparinases. Most preferably, mammalian host cells include brain and neuroblastoma cells.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains expression control sequences which contain transcriptional regulatory information and such sequences are "operably linked" to the nucleotide sequence which encodes the polypeptide.

An operable linkage is a linkage in which a sequence is connected to a regulatory sequence (or sequences) in such a way as to place expression of the sequence under the influence or control of the regulatory sequence. Two DNA sequences (such as a heparinases encoding sequence and a promoter region sequence linked to the 5' end of the encoding sequence) are said to be operably linked if induction of promoter function results in the transcription of the heparinases encoding sequence mRNA and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the expression regulatory sequences to direct the expression of the heparinases, or (3) interfere with the ability of the heparinases template to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence.

The precise nature of the regulatory regions needed for gene expression may vary between species or cell types, but in general includes,

as necessary, 5' non-transcribing and 5' non-translating (non-coding) sequences involved with initiation of transcription and translation respectively, such as the TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing control sequences will include 5 a region which contains a promoter for transcriptional control of the operably linked gene.

If desired, a fusion product of the heparinases may be constructed. For example, the sequence coding for heparinases may be linked to a signal sequence which will allow secretion of the protein from, or the 10 compartmentalization of the protein in, a particular host. Such signal sequences maybe designed with or without specific protease sites such that the signal peptide sequence is amenable to subsequent removal. Alternatively, the native signal sequence for this protein may be used.

Transcriptional initiation regulatory signals can be selected which 15 allow for repression or activation, so that expression of the operably linked genes can be modulated.

Based on this disclosure, one skilled in the art can readily place the sequences of the present invention in additional expression vectors and transform into a variety of bacteria to obtain recombinant heparinase II or 20 heparinase III.

Once the vector or DNA sequence containing the construct(s) is prepared for expression, the DNA construct(s) is introduced into an appropriate host cell by any if a variety of suitable means, including transfection. After the introduction of the vector, recipient cells are grown 25 in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of heparinase I, II or III, or in the production of a fragment of one of these proteins. This expression can take place in a continuous manner in the

transformed cells, or in a controlled manner, for example, expression which follows induction of differentiation of the transformed cells (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like).

The expressed protein is isolated and purified in accordance with conventional conditions, such as extraction, precipitation, chromatography, electrophoresis, or the like. Detailed procedures for the isolation of the heparinases is discussed in detail in the examples below.

The invention further provides functional derivatives of the sequences of heparinase II, heparinase III, and the modified ribosome binding site. As used herein, the term "functional derivative" is used to define any DNA sequence which is derived by the original DNA sequence and which still possesses the biological activities of the native parent molecule. A functional derivative can be an insertion, a deletion, or a substitution of one or more bases in the original DNA sequence. The substitutions can be such that they replace a native amino acid with another amino acid that does not substantially effect the functioning of the protein. Those skilled in the art will recognize that likely substitutions include positively the functioning of the protein, such as a small, neutrally charged amino acid replacing another small, neutrally charged amino acid.

Those of skill in the art will recognize that functional derivatives of the heparinases can be prepared by mutagenesis of the DNA using one of the procedures known in the art, such as site-directed mutagenesis. In addition, random mutagenesis can be conducted and mutants retaining function can be obtained through appropriate screening.

The antibodies of the present invention include monoclonal and polyclonal antibodies, as well fragments of these antibodies. Fragments of the antibodies of the present invention include, but are not limited to, the Fab, the Fab2, and the Fc fragment.

The invention also provides hybridomas which are capable of producing the above-described antibodies. A hybridoma is an immortalized cell line which is capable of secreting a specific monoclonal antibody.

- 5 In general, techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody are well-known in the art (Campbell, A.M., "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology," Elsevier Science Publishers, Amsterdam, The Netherlands (1984);
10 St. Groth et al., *J. Immunol. Methods* 35:1-21 (1980)).

Any mammal which is known to produce antibodies can be immunized with the pseudogene polypeptide. Methods for immunization are well-known in the art. Such methods include subcutaneous or interperitoneal injection of the polypeptide. One skilled in the art will
15 recognize that the amount of heparinase used for immunization will vary based on the animal which is immunized, the antigenicity of the peptide and the site of injection.

- The protein which is used as an immunogen may be modified or administered in an adjuvant in order to increase the protein's antigenicity.
20 Methods of increasing the antigenicity of a protein are well-known in the art and include, but are not limited to coupling the antigen with a heterologous protein (such as globulin or β -galactosidase) or through the inclusion of an adjuvant during immunization.

For monoclonal antibodies, spleen cells from the immunized animals
25 are removed, fused with myeloma cells, such as SP2/0-Ag14 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells.

Any one of a number of methods well known in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz et al., *Exp. Cell Res.* 175:109-124 (1988)).

Hybridomas secreting the desired antibodies are cloned and the class and subclass is determined using procedures known in the art (Campbell, A.M., *Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, 10 Amsterdam, The Netherlands (1984)).

For polyclonal antibodies, antibody containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures.

The present invention further provides the above-described antibodies in detectably labelled form. Antibodies can be detectably labelled through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, etc.), fluorescent labels (such as FITC or rhodamine, etc.), paramagnetic atoms, chemiluminescent labels, and the like. Procedures for accomplishing such labelling are well-known in the art; for example, see Sternberger, L.A. et al., *J. Histochem. Cytochem.* 18:315 (1970); Byer, E.A. et al., *Meth. Enzym.* 62:308 (1979); Engval, E. et al., *Immunol.* 109:129 (1972); Goding, J.W., *J. Immunol. Meth.* 13:215 (1976).

The present invention further provides the above-described antibodies immobilized on a solid support. Examples of such solid supports include plastics, such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well

known in the art (Weir *et al.*, *Handbook of Experimental Immunology*, 4th Ed., Blackwell Scientific Publications, Oxford, England (1986)). The immobilized antibodies of the present invention can be used for immunoaffinity purification of heparinases.

Having now generally described the invention, the same will be understood by a series of specific examples, which are not intended to be limiting.

EXAMPLE 1: Purification of Heparinases

Heparin lyase enzymes were purified from cultures of *Flavobacterium heparinum*. *F. heparinum* was cultured in a 15 L computer-controlled fermenter using a variation of the defined nutrient medium described by Galliher *et al.*, *Appl Environ. Microbiol.* 41(2):360-365 (1981). Those fermentations designed to produce heparin lyases incorporate semi-purified heparin (Celsus Laboratories) in the media at a concentration of 1.0 g/L as the inducer of heparinase synthesis. Cells were harvested by centrifugation and the desired enzymes released from the periplasmic space by a variation of the osmotic shock procedure described by Zimmermann and Cooney, U.S. Patent No. 5,262,325, herein incorporated by reference.

A semi-purified preparation of the heparinase enzymes was achieved by a modification of the procedure described by Zimmermann *et al.*, U.S. Patent No. 5,262,325. Proteins from the crude osmolate were adsorbed onto cation exchange resin (CBX, J.T. Baker) at a conductivity of 1 - 7 μ mho. Unbound proteins from the extract were discarded and the resin packed into a chromatography column (5.0 cm i.d. x 100 cm). The bound proteins eluted at a linear flow rate of 3.75 $\text{cm} \cdot \text{min}^{-1}$ with step gradients of 0.01 M phosphate, 0.01 M phosphate/0.1 M sodium chloride,

0.01 M phosphate/0.25 M sodium chloride and 0.01 M phosphate/1.0 M sodium chloride, all at pH 7.0 +/- 0.1. Heparinase II elutes in the 0.1 M NaCl fraction, while heparinases 1 and 3 elute in the 0.25 M fraction.

Alternately, the 0.1 M sodium chloride step was eliminated and the
5 three heparinases co-eluted with 0.25 M sodium chloride. The heparinase fractions were loaded directly onto a column containing cellufine sulfate (5.0 cm i.d. x 30 cm, Amicon) and eluted at a linear flow rate of 2.50 cm⁻¹ min⁻¹ with step gradients of 0.01 M phosphate, 0.01 M phosphate/0.2 M sodium chloride, 0.01 M phosphate/0.4 M sodium chloride and 0.01 M 10 phosphate/1.0 M sodium chloride, all at pH 7.0 +/- 0.1. Heparinase II and 3 elute in the 0.2 M sodium chloride fraction while heparinase I elutes in the 0.4 M fraction.

The 0.2 M sodium chloride fraction from the cellufine sulfate column was diluted with 0.01 M sodium phosphate to give a conductance of less
15 than 5 μ mhos. The solution was further purified by loading the material onto a hydroxylapatite column (2.6 cm i.d. x 20 cm) and eluting the bound protein at a linear flow rate of 1.0 cm⁻¹ min⁻¹ with step gradients of 0.01 M phosphate, 0.01 M phosphate/0.35 M sodium chloride, 0.01 M phosphate/0.45 M sodium chloride, 0.01 M phosphate/0.65 M sodium 20 chloride and 0.01 M phosphate/1.0 M sodium chloride, all at pH 7.0 +/- 0.1. Heparinase III elutes in a single protein peak in the 0.45 M sodium chloride fraction while heparinase III elutes in a single protein peak in the 0.65 M sodium chloride fraction.

Heparinase I was further purified by loading material from the
25 cellufine sulfate column, diluted to a conductivity less than 5 μ mhos, onto a hydroxylapatite column (2.6 cm i.d. x 20 cm) and eluting the bound protein at a linear flow rate of 1.0 cm⁻¹ min⁻¹ with a linear gradient of phosphate (0.01 to 0.25 M) and sodium chloride (0.0 to 0.5 M). Heparinase

I elutes in a single protein peak approximately mid-way through the gradient.

The heparinase enzymes obtained by this method were analyzed by SDS-PAGE using the technique of Laemmli, *Nature* 227: 680-685 (1970), 5 and the gels quantified by a scanning densitometer (Bio-Rad, Model GS-670). Heparinases I, II and III displayed molecular weights of 42,500+/-2,000, 84,000+/-4,200 and 73,000+/-3,500 Daltons, respectively. All proteins displayed purities of greater than 99 %. Purification results for the heparinase enzymes are shown in Table 1.

10 Heparinase activities were determined by the spectrophotometric assay described by Yang *et al.* A modification of this assay incorporating a reaction buffer comprised of 0.018 M Tris, 0.044 M sodium chloride and 1.5 g/L heparan sulfate at pH 7.5 was used to measure heparan sulfate degrading activity.

15 Recombinant heparinase I forms intracellular inclusion bodies which require denaturation and protein refolding to obtain active heparinase. Two solvents, urea and guanidine hydrochloride, were examined as solubilizing agents. Of these, only guanidine HCl, at 6 M, was able to solubilize the heparinase I inclusion bodies. However, the highest degree 20 of purification was obtained by sequentially washing the inclusion bodies in 3 M urea and 6 M guanidine HCl. The urea wash step served to removed contaminating *E. coli* proteins and cell debris prior to solubilizing of the aggregated heparinase I by guanidine HCl.

Recombinant heparinase I was prepared by growing *E. coli* 25 Y1090(pGHepl), a strain harboring a plasmid containing the heparinase I gene expressed from tandem tac promoters, in Luria broth with 0.1 M IPTG. The cells were concentrated by centrifugation and resuspended in 1/10th volume buffer containing 0.01 M sodium phosphate and 0.2 M

SUBSTITUTE SHEET (RULE 26)

sodium chloride at pH 7.0. The cells were disrupted by sonication, 5 minutes with intermittent 30 second cycles, power setting #3 and the inclusion bodies concentrated by centrifugation, 7,000 x g, 5 minutes. The pellets were washed two times with cold 3 M urea for 2 hours at pH, 7.0
5 and the insoluble material recovered by centrifugation. Heparinase I was unfolded in 6 M guanidine HCl containing 50 mM DTT and refolded by dialysis into 0.1 M ammonium sulfate. Additional contaminating proteins precipitated in the 0.1 M ammonium sulfate and could be removed by centrifugation. Heparinase I purified by this method had a specific activity
10 of 42.21 IU/mg and was 90 % pure by SDS-PAGE/ scanning densitometry analysis. The enzyme can be further purified by cation exchange chromatography, as described above, yielding a heparinase I preparation that is more than 99 % pure by SDS-PAGE/ scanning densitometry analysis.

15 **EXAMPLE 2: Characterization of Heparinases**

The molecular weight and kinetic properties of the three heparinase enzymes have been accurately reported by Lohse and Linhardt, *J. Biol. Chem.* 267:24347-24355 (1992). However, an accurate characterization of the proteins' post-translational modifications had not been carried out.
20 Heparinases I, II and III, purified as described herein, were analyzed for the presence of carbohydrate moieties. Solutions containing 2 ug of heparinases I, II and III and recombinant heparinase I were brought to pH 5.7 by adding 0.2 M sodium acetate. These protein samples underwent carbohydrate biotinylation following protocol 2a, described in the
25 GlycoTrack kit (Oxford Glycosystems). 30 µl of each biotinylated protein solution was subjected to SDS-PAGE (10% gel) and transferred by electroblotting at 170 mA constant current to a nitrocellulose membrane. Detection of the biotinylated carbohydrate was accomplished by an

alkaline phosphatase-specific color reaction after attachment of a streptavidin-alkaline phosphatase conjugate to the biotin groups. These analyses revealed that heparinases I and II are glycosylated and heparinase III and recombinant heparinase I are not.

5 Polyclonal antibodies generated in rabbits injected with wild type heparinase I could be fractionated into two populations as described below. It appears that one of these fractions recognizes a post-translational moiety common to proteins made in *F. heparinum*, while the other fraction specifically recognizes amino acid sequences contained in
10 heparinase I. All heparinase enzymes made in *F. heparinum* were recognized by the "non-specific" antibodies but not heparinase made in *E. coli*. The most likely candidate for the non-protein antigenic determinant from heparinase I is the carbohydrate component; thus, the Western blot experiment indicates that all lyases made in *F. heparinum* are glycosylated.
15 Purified heparinases II and III were analyzed by the technique of Edman to determine the N-terminal amino acid residue of the mature protein. However, the Edman chemistry was unable to liberate an amino acid, indicating that a post-translational modification had occurred at the N-terminal amino acid of both heparinases. One nmol samples of
20 heparinases II and III were used for deblocking with pyroglutamate aminopeptidase. Control samples were produced by mock deblocking 1 nmol protein samples without adding pyroglutamate aminopeptidase. All samples were placed in 10 mM NH₄CO₃, pH 7.5, and 10 mM DTT (100 µl final volume). To non-control samples, 1 mU of pyroglutamate
25 aminopeptidase was added and all samples were incubated for 8 hr at 37°C. After incubation, an additional 0.5 mU of pyroglutamate aminopeptidase was added to non-control samples and all samples were incubated for an additional 16 h at 37°C.

21

Deblocking buffers were exchanged for 35% formic acid using a 10,000 Dalton cut-off Centricon unit and the sample was dried under vacuum. The samples were subjected to amino acid sequence analysis according to the method of Edman.

5 The properties of the three heparinase proteins from *Flavobacterium heparinum* are listed in Table 2.

Heparinases II and III were digested with cyanogen bromide in order to produce peptide fragments for isolation. The protein solutions (1-10 mg/ml protein concentration) were brought to a DTT concentration of 10 0.1 M, and incubated at 40°C for 2 hr. The samples were frozen and lyophilized under vacuum. The pellet was resuspended in 70% formic acid, and nitrogen gas was bubbled through the solution to exclude oxygen. A stock solution of CNBr was made in 70% formic acid and the stock solution was bubbled with nitrogen gas and stored in the dark for short time 15 periods. For addition of CNBr, a 500 to 1000 times molar excess of CNBr to methionine residues in the protein was used. The CNBr stock was added to the protein solutions, bubbled with nitrogen gas and the tube was sealed. The reaction tube was incubated at 24°C for 20 hr, in the dark.

The samples were dried down partially under vacuum, water was 20 added to the sample, and partial lyophilization was repeated. This washing procedure was repeated until the sample pellets were white. The peptide mixtures were solubilized in formic acid and applied to a Vydac C₁₈ reverse phase HPLC column (4.6 mm i.d. x 30 cm) and individual peptide fragments eluted at a linear flow rate of 6.0 cm•min⁻¹ with a linear 25 gradient of 10 to 90 % acetonitrile in 1 % trifluoroacetic acid. Fragments recovered from these reactions were subjected to amino acid sequence determination using an Applied Biosystems 745A Protein Sequencer. Three peptides isolated from heparinase II gave sequences: EFPEMYNLAAGR

(SEQU ID NO:5), KPADIPEVKDGR (SEQU ID NO:6), and LAGDFVTGKILAQGFG PDNQTPDYTYL (SEQU ID NO:7) and were named peptides 2A, 2B and 2C respectively. Three peptides from heparinase III gave sequences: LIK-NEVRWQLHRVK (SEQU ID NO:8), VLKASPPGEFHAQPDNGTFELFI (SEQU ID 5 NO:9) and KALVHWFWPHKGYGYFDYGKDIN (SEQU ID NO:10) and were named peptides 3A, 3B and 3C, respectively.

EXAMPLE 3: Antibodies to the Heparinase Proteins

Heparinases I, II and III and recombinant heparinase I, purified as 10 described herein, were used to generate polyclonal antibodies in rabbits. Each of heparinase I, II and III was carried through the following standard immunization procedure: The primary injection consisted of 0.5 - 1.0 mg of purified protein dissolved in 1 ml of sterile phosphate buffered Saline, which was homogenized with 1 ml of Freund's adjuvant (Cedarlane 15 Laboratories Ltd.). This protein-adjuvant emulsion was used to inject New Zealand White female rabbits; 1 ml per rabbit, 0.5 ml per rear leg, i.m., in the thigh muscle near the hip. After 2 to 3 weeks, the rabbits were given an injection boost consisting of 0.5 - 1.0 mg of purified protein dissolved in sterile phosphate buffered Saline homogenized with 1 ml of incomplete 20 Freund's adjuvant (Cedarlane Laboratories, Ltd.). Again after 2 to 3 weeks, the rabbits were given a third identical injection boost.

A blood sample was collected from each animal from the central artery of the ear approximately 10 days following the final injection boost. Serum was prepared by allowing the sample to clot for 2 hours at 22°C 25 followed by overnight incubation at 4°C, and clearing by centrifugation at 5,000 rpm for 10 min. The antisera were diluted 1:100,000 in Tris-buffered Saline (pH 7.5) and carried through Western blot analysis to identify those sera containing anti-heparinase I, II or III antibodies.

Antibodies generated against wild type heparinase I, but not recombinant heparinase I, displayed a high degree of cross reactivity against other *F. heparinum* proteins. This was likely due to the presence of an antigenic post-translational modification common to *F. heparinum*

5 proteins but not found on proteins synthesized in *E. coli*. To explore this further, recombinant heparinase I was immobilized onto Sepharose beads and packed into a chromatography column. Purified anti-heparinase I (wild type) antibodies were loaded onto the column and the unbound fraction collected. Bound antibodies were eluted in 0.1 M glycine, pH 2.0.

10 IgG was found in both the unbound and bound fractions and subsequently used in Western blot experiments. Antibody isolated from the unbound fraction non-specifically recognized *F. heparinum* proteins but no longer detected recombinant heparinase I (*E. coli*), while the antibody isolated from the bound fraction only recognized heparinase I, whether synthesized

15 in *F. heparinum* or *E. coli*. This result indicated that, as hypothesized, two populations of antibodies are formed by exposure to the wild-type heparinase I antigen: one specific for the protein backbone and the other recognizing a post-translationally modified moiety common to *F. heparinum* proteins.

20 This finding provides both a means to purify specific anti-heparinase antibodies and a tool for characterizing the wild-type heparinase I protein.

EXAMPLE 4: Construction of a *F. heparinum* Gene Library

A *Flavobacterium heparinum* chromosomal DNA library was

25 constructed in lambda phage DASHII. 0.4 ug of *F. heparinum* chromosomal DNA was partially digested with restriction enzyme *Sau*3A to produce a majority of fragments around 20 kb in size, as described in Maniatis, et al., Molecular Cloning Manual, Cold Spring Harbor (1982). This DNA was

phenol/chloroform extracted, ethanol precipitated, ligated with λ DASHII arms and packaged with packaging extracts from a λ DASHII/*Bam*HI Cloning Kit (Stratagene, La Jolla, CA). The library was titered at approximately 10^{-5} pfu/ml after packaging, amplified to 10^{-8} pfu/ml by 5 the plate lysis method, and stored at -70°C as described by Silhavy, T.J., et al. in *Experiments in Molecular Genetics*, Cold Spring Harbor Laboratory, 1992.

The *F. heparinum* chromosomal library was titered to about 300 pfu/plate, overlaid on a lawn of *E. coli*, and allowed to transfect the cells 10 overnight at 37°C, forming plaques. The phage plaques were transferred to nitrocellulose paper, and the phage DNA bound to the filters, as described in Maniatis, et al., *ibid.*

15 **EXAMPLE 5: A Modified Ribosome Binding Region for
the Expression of *Flavobacterium heparinum*
Glycosaminoglycan Lyases**

The gene for the mature heparinase I protein was cloned into the *Eco*RI site of the vector, pB9, where its expression was driven by two repeats of the tac promoter (from expression vector, pKK223-3, Brosius, 20 and Holy, *Proc. Natl. Acad. Sci. USA* 81: 6929-6933 (1984)). In this vector, pBhep, the first codon, ATG, for heparinase 1 is separated by 10 nucleotides from a minimal Shine-Dalgarno sequence AGGA (Shine and Dalgarno, *Proc. Natl. Acad. Sci. USA* 71:1342-1346 (1974)), Figure 1. This construct was transformed into the *E. coli* strain, JM109, grown at 37° C 25 and induced with 1mM IPTG, 2 hours before harvesting. Cells were lysed by sonication, the cell membrane fraction was pelleted and the supernatant was saved. The membrane fraction was resuspended in 6M guanidine-HCl in order to solubilize inclusion bodies containing the recombinant heparinase I enzyme. The soluble heparinase I was refolded

by diluting in 20mM phosphate buffer. The enzyme activity was determined in the refolded pellet fraction, and in the supernatant fraction. Low levels of activity were detected in the supernatant and the pellet fractions. Analysis of the fractions by SDS-PAGE indicated that both 5 fractions may contain minor bands corresponding to the recombinant heparinase I.

In an attempt to increase expression levels from pBhep, two mutations were introduced as indicated in Figure 1. The mutations were produced to improve the level of translation of the heparinase I mRNA by 1.0 increasing the length of the Shine-Dalgarno sequence and by decreasing the distance between the Shine-Dalgarno sequence and the ATG-start site. Using PCR, a single base mutation converting an A to a G improved the Shine-Dalgarno sequence from a minimal AGGA sequence to AGGAG while decreasing the distance between the Shine-Dalgarno sequence and the 1.5 translation start site from 10 to 9 base pairs. This construct was named pGhep. In the second construct, pΔ4hep, 4 nucleotides (AAC) were deleted using PCR, in order to lengthen the Shine-Dalgarno sequence to AGGAG as well as moving it to within 5 base pairs of the ATG-start site.

The different constructs were analyzed as described above. Refolded 2.0 pellets from *E. coli* transformed with pGhep displayed approximately a 7X increase in heparinase I activity, as compared to refolded pellets from *E. coli* containing pBhep. On the other hand, *E. coli* containing pΔ4hep displayed 2-3 times less activity than the pBhep containing *E. coli*. The levels of heparinase I activity in the supernatants were similar.

2.5 Plasmid, pBhep, was digested with *Eco*RI and treated with S1 nuclease to form blunt-ended DNA. The plasmid DNA was then digested with *Bam*HI and the single-stranded ends were made double-stranded by filling-in with Klenow fragment. The blunt-end DNA was ligated and

transformed into *E. coli* strain FTB1. A plasmid which contained a unique *Bam*HI site and no heparinase I gene DNA was purified from a kanamycin resistant colony and was designated plasmid, pGB. DNA sequence analysis revealed that plasmid pGB contained the modified ribosome binding site,
5 shown in Figure 1.

EXAMPLE 6: Nucleic Acid Encoding Heparinase II

Four "guessmer" oligonucleotides were designed using information from two peptide sequences 2A and 2B and use of the consensus codons
10 for *Flavobacterium*, shown in Table 3. These were:
5'-GAATTCCCTGAGATGTACAATCTGGCCGC-3' (SEQU ID NO:11),
5'-CCGGCAGCCAGATTGTACATTCAGG-3' (SEQU ID NO:12),
5'-AAACCCGCCGACATCCCCAACGTAAGAAAAGA-3' (SEQU ID NO:13), and
5'-CGAAAGTCTTTACTTCGGGAATGTCGGC-3' (SEQU ID NO:14),
15 named 2-1, 2-2, 2-3 and 2-4, respectively. The oligonucleotides were synthesized with a Bio/CAN (Mississauga, Ontario) peptide synthesizer. Pairs of these oligonucleotides were used as primers in PCR reactions. *F. heparinum* chromosomal DNA was digested with restriction endonucleases *Sal*I, *Xba*I or *Not*I, and the fragmented DNA combined for use as the
20 template DNA. Polymerase chain reaction mixtures were produced using the DNA Amplification Reagent Kit (Perkin Elmer Cetus, Norwalk, CT). The PCR amplifications were carried out in 100 µl reaction volume containing 50 mM KCl, 10 mM Tris HCl, pH 9, 0.1% Triton X-100, 1.5 mM MgCl₂, 0.2 mM of each of the four deoxyribose nucleotide triphosphates (dNTPs), 100
25 pmol of each primer, 10 ng of fragmented *F. heparinum* genomic DNA and 2.5 units of *Taq* polymerase (Bio/CAN Scientific Inc., Mississauga, Ontario). The samples were placed on an automated heating block (DNA thermal cycler, Barnstead/Thermolyne Corporation, Dubuque, IA) programmed for

step cycles of: denaturation temperature 92°C (1 minute), annealing temperatures of 37°C, 42°C or 45°C (1 minute) and extension temperature 72°C (2 minutes). These cycles were repeated 35 times. The resulting PCR products were analyzed on a 1.0% agarose gel containing 0.6 ug/ml 5 ethidium bromide, as described by Maniatis, *et al., ibid.* DNA fragments were produced by oligonucleotides 2-2 and 2-3. The fragments, 250 bp and 350 bp in size, were first separated on 1% agarose gel electrophoresis, and the DNA extracted from using the GENECLEAN I kit (Bio/CAN Scientific, Mississauga, Ontario). Purified fragments were ligated into pTZ/PC (Tessier 10 and Thomas, unpublished) previously digested with *NotI*, Figure 2, and the ligation mixture used to transform *E. coli* FTB1, as described in Maniatis *et al., ibid.* All restriction enzymes and T4 DNA ligase were purchased from New England Biolabs (Mississauga, Ontario).

Strain FTB1 was constructed in our laboratory. The F' episome from 15 the XL-1 Blue *E. coli* strain (Stratagene, La Jolla, CA), which carries the *lac I^q* repressor gene and produces 10 times more *lac* repressor than wild type *E. coli*, was moved, as described by J. Miller, *Experiments in Molecular Genetics*, Cold Spring Harbor Laboratory (1972), into the TB1 *E. coli* strain, described by Baker, T.A., *et al., Proc. Natl. Acad. Sci.* 81:6779-6783 (1984). 20 The FTB1 background permits a more stringent repression of transcription from plasmids carrying promoters with a *lac* operator (i.e. *lac* and *Taq* promoters). Colonies resulting from the transformation of FTB1 were selected on LB agar containing ampicillin and screened using the blue/white screen provided by X-gal and IPTG included in the agar 25 medium, as described by Maniatis, *et al., ibid.* Transformants were analyzed by colony cracking and mini-preparations of DNA were made for enzyme restriction analysis using the RPM kit (Bio/CAN Scientific Inc.,

Mississauga, Ontario). Ten plasmids contained inserts of the correct size, which were released upon digestion with *EcoRI* and *HindIII*.

DNA sequencing revealed that one of the plasmids, pCE14, contained a 350 bp PCR fragment had the expected DNA sequence as derived from peptide 2C. DNA sequences were determined by the dideoxy-chain termination method of Sanger *et al.*, *Proc. Natl. Acad. Sci.* 74:5463-5467 (1978). Sequencing reactions were carried out with the Sequenase Kit (U.S. Biochemical Corp., Cleveland, Ohio) and ^{35}S -dATP (Amersham Canada Ltd., Oakville, Ontario, Canada), as specified by the supplier.

The heparinase II gene was cloned from a *F. heparinum* chromosomal DNA library, Figure 2, constructed as described above. Ten plaque-containing filters were hybridized with the DNA probe, produced from the gel purified insert of pCE14, which was labeled using a Random Labeling Kit (Boehringer Mannheim Canada, Laval, Quebec). Plaque hybridization was carried out, as described in Maniatis *et al.*, *ibid.*, at 65°C for 16 hours in a Tek Star hybridization oven (Bio/CAN Scientific, Mississauga, Ontario). Subsequent washes were performed at 65°C: twice for 15 min. in 2X SSC, once in 2X SSC/0.1% SDS for 30 min. and once in 0.5X SSC/0.1% SDS for 15 min. Positive plaques were harvested using plastic micropipette tips and confirmed by dot blot analysis, as described by Maniatis *et al.*, *ibid.* Six of the phages, which gave strong hybridization signals, were used for Southern hybridization analysis, as described by Southern, E.M., *J. Mol. Biol.* 98:503-517 (1975). This analysis showed that one phage, HIIS, contained a 5.5 kb *XbaI* DNA fragment which hybridized with the probe. Cloning the 5.5 kb *XbaI* fragment into the *XbaI* site of any of following vectors: pTZ/PC, pBluescript (Stratagene, La Jolla CA), pUC18 (described in Yanisch-Perron *et al.*, *Gene* 33:103-119 (1985)), and pOK12 (described in Vierra and Messing, *Gene* 100:189-194 (1991)), was unsuccessful, even though the

FTB1 background was used to repress plasmid promoter-derived transcription. Vector, pOK12, a low copy number plasmid derived from pACYC184 (approximately 10 copies/cell, Chang, A.C.Y. and Cohen, S.N., *J. Bact.* 134:1141-1156 (1978)) was used in an attempt to circumvent the toxic effects of a foreign DNA fragment in *E. coli* by minimizing the number of copies of the toxic foreign fragment. In addition, insertion of the entire *NotI* chromosomal DNA insert of the HIIS phage into plasmid pOK12 plasmid, was unsuccessful. It was concluded that this region of *F. heparinum* chromosome imparts a negative-selective effect on any *E. coli* cells that harbor it. This toxic affect had not been observed previously with other *F. heparinum* chromosomal DNA fragments.

A second strategy employed to circumvent the unexpected problem of *F. heparinum* DNA toxicity in *E. coli* was to digest the chromosomal DNA fragment with a restriction endonuclease which would divide the fragment, and if possible the heparinase II, gene into two pieces, Figure 2. These fragments could be cloned individually. DNA sequence analysis of the PCR insert in plasmid, pCE14, demonstrated that *BamHI* and *EcoRI* sites were present in the insert. Hybridization experiments also demonstrated that the *BamHI* digested *F. heparinum* DNA in phage HIIS produced two bands 1.8 and 5.5 kb in size. Analysis of hybridization data indicated that the 1.8 kb band contains the 5' end and the 5.5 kb band contains the 3' end of the gene. Furthermore, a 5 kb *EcoRI* *F. heparinum* chromosomal DNA fragment hybridized with the PCR probe. The 1.8, 5, and 5.5 kb fragments containing heparinase II gene sequences were inserted into pBluescript, as described above. Two clones, pBSIB6-7 and pBSIB6-21, containing the 5.5 kb *BamHI* insert in different orientations were isolated and one plasmid, pBSIB213, was isolated which contained the 1.8 kb

BamHI fragment. No clones containing the 5 kb *EcoRI* fragment were isolated, even though extensive screening of possible clones was done.

The molecular weight of heparinase II protein is approximately 84 kD, so the size of the corresponding gene would be approximately 2.4 kb.

5 The 1.8 and 5.5 kb *BamHI* chromosomal DNA fragments could include the entire heparinase II gene. The plasmids pBSIB6-7, pBSIB6-21 and pBSIB2-13, Figure 2, were used to produce nested deletions with the Erase-a-Base system (Promega Biotec, Madison Wis.). These plasmids were used as templates for DNA sequence analysis using universal and reverse
10 primers and oligonucleotide primers derived from known heparinase II sequence. Because parts of the gene were relatively G-C rich and contained numerous strong, secondary structures, the sequence analysis was, at times, performed using reactions in which the dGTP was replaced by dITP. Analysis of the DNA sequence, Figure 4, indicated that there was
15 a single, continuous open reading frame containing codons for 772 amino acid residues, Figure 5. Searching for a possible signal peptide sequence using Geneworks (Intelligenetics, Mountain View, CA) suggested that there are two possible sites for processing of the protein into a mature form: Q-
20 26 (glutamine) and D-30 (aspartate). N-terminal amino acid sequencing of deblocked, processed heparinase II indicated that the mature protein begins with Q-26, and contains 747 amino acids with a calculated molecular weight of 84,545 Daltons, Figure 5.

EXAMPLE 7: Expression of Heparinase II in *E. coli*

25 The vector, pGB, was used for heparinase II expression in *E. coli*, Figure 3. pGB contains the modified ribosome binding region from pGhep, Figure 1, and a unique *BamHI* site, whereby expression of a DNA fragment inserted into this site is driven by a double tac promoter. The vector also

includes a kanamycin resistance gene, and the *lac* Iq gene to allow induction of transcription with IPTG. Initially, a gel purified 5.5 kb *BamHI* fragment from pBSIB6-21 was ligated with *BamHI* digested pGB and transformed into FTB1, which was selected on LB agar with kanamycin.

- 5 Six of the resulting colonies contained plasmids with inserts in the correct orientation for expression of the open reading frame. *PstI* digestion and religation of one of the plasmids, forming pGBIID, deleted 3.5 kb of the 5.5 kb *BamHI* fragment and removed a *BamHI* site leaving only one *BamHI* site directly after the Shine-Dalgarno sequence. Finally, two synthetic
10 oligonucleotides were designed: 5'-TGAGGATTCAATGCAAACCAAGGCCGATGT GGTTTGGAA-3' (SEQU ID NO:15), and 5'-GGAGGATAACCACATTGAGCATT-3' (SEQU ID NO:16) for use in a PCR to produce a fragment containing a *BamHI* site and an ATG start codon upstream of the mature protein encoding sequence and a downstream *BamHI* site, Figure 3. Lambda clone HII-I,
15 isolated at the same time as lambda clone HIIS, was used as template DNA.

Cloning the blunt-end PCR product into pTZ/PC was unsuccessful, using FTB1 as the host. Cloning the *BamHI* digested PCR product into the *BamHI* site of pBluescript, again using FTB1 as the host, resulted in the isolation of 2 plasmids containing the PCR fragment, after screening of 150
20 possible clones. One of these, pBSQTK-9, which was sequenced with reverse and universal primers, contained an accurate reproduction of the DNA sequence from the heparinase II gene. The *BamHI* digested PCR fragment from pBSQTK-9 was inserted into the *BamHI* site of pGBIID in such orientation that the ATG site was downstream of the Shine-Dalgarno
25 sequence. This construct, pGBH2, placed the mature heparinase II gene under control of the tac promoters in pGB, Figure 3. Strain *E. coli* FTB1(pGBH2) was grown in LB medium containing 50 ug/ml kanamycin at 37°C for 3 h. Induction of the tac promoter was achieved by adding 1

mmol IPTG and the culture placed at either room temperature or 30°C. Heparin and heparan sulfate degrading activity was measured in the cultures after growth for 4 hours using the method described by Yang *et al.*, *ibid.* Heparin degrading activities of 0.36 and 0.24 IU/mg protein and 5 heparan sulfate degrading activities of 0.49 and 0.44 IU/mg protein were observed at room temperature and 30°C, respectively.

EXAMPLE 8: Nucleic Acid Encoding Heparinase III

The amino acid sequence information obtained from peptides 10 derived from heparinase III, Figure 9, purified as described herein, reverse translated into highly degenerate oligonucleotides. Therefore, a cloning strategy relying on the polymerase chain reaction amplification of a section of the heparinase III gene, using oligonucleotides synthesized on the basis of amino acid sequence information, required eliminating some of 15 the DNA sequence possibilities. An assumed codon usage was calculated based on known DNA sequences for genes from other *Flavobacterium* species. Sequences for 17 genes were analyzed and a codon usage table was compiled, Table 3.

Four oligonucleotides were designed by choosing each codon 20 according to the codon usage table. These were: 5'-GAATTCCATCAGTTTCAG CCGCATAAA-3' (SEQU ID NO:17), 5'-GAATTCTTATGCGGCTGAAACTGATG-3' (SEQU ID NO:18), 5'-GAATTCCGCCGGCGAATTTCATGC-3' (SEQU ID NO:19) and 5'-GAATTCGCATGAAATTGCCCGGG-3' (SEQU ID NO:20), and were named oligonucleotides 3-1, 3-2, 3-3 and 3-4, respectively. These 25 oligonucleotides were used in all possible combinations, in an attempt to amplify a portion of the heparinase III gene using the polymerase chain reaction. The PCR amplifications were carried out as described above. Cycles of: denaturation temperature 92° C (1 minute), annealing

temperatures ranging from 37° to 55° C, (1 minute) and extension temperature 72° C (2 minutes) were repeated 35 times. Analysis of the PCR reactions as described above demonstrated that no DNA fragments were produced by these experiments.

5 A second set of oligonucleotides was synthesized and was comprised of 32 base sequences, in which the codon usage table was used to guess the third position of only half of the codons. The nucleotides within the parentheses indicate degeneracies of two or four bases at a single site. These were:

10 5'-GG(ACGT)GAATTCATGCCAGCC(ACGT)GA(CT)AATGG(ACGT)AC-3' (SEQU ID NO:21),
5'-GT(ACGT)CCATT(AG)TC(ACGT)GGCTGGGCATGAAATTC(ACGT)CC-3' (SEQU ID NO:22),
5'-GT(ACGT)CATCAGTT(CT)CAGCC(ACGT)CATAAAGG(ACGT)TATGG-3' (SEQU
15 ID NO:23), and
5'-CCCAT(ACGT)CCTTTATG(ACGT)GGCTG(AG)AACTGATG(ACGT)AC-3'
(SEQU ID NO:24), and were named oligonucleotides 3-5, 3-6, 3-7 and 3-8, respectively. These oligonucleotides were used in an attempt to amplify a portion of the heparinase III gene using the polymerase chain reaction,
20 and the combination of 3-6 and 3-7 gave rise to a specific 983 bp PCR product. An attempt was made to clone this fragment by blunt end ligation into *E. coli* vector, pBluescript, as well as two specifically designed vectors for the cloning of PCR products, pTZ/PC and pCRII from the TA cloning TM kit (InVitrogen Corporation, San Diego, CA). All of these
25 constructs were transformed into the FTB1 *E. coli* strain. Transformants were first analyzed by colony cracking, and subsequently mini-preparations of DNA were made for enzyme restriction analysis. No clones containing this PCR fragment were isolated.

A third set of oligonucleotides was synthesized incorporating *BamHI* endonuclease sequences on the ends of the 3-6 and 3-7 oligonucleotide sequences. A 999 base pair DNA sequence was obtained using the polymerase chain reaction with *F. heparinum* chromosomal DNA as the target. Attempts were made to clone the amplified DNA into the *BamHI* site of the high copy number plasmid pBluescript and the low copy number plasmids pBR322 and pACYC184. All of these constructs were again transformed into the FTB1 *E. coli* strain. More than 500 candidates were screened, yet no transformants containing a plasmid harboring the *F. heparinum* DNA were obtained. Once again, it was concluded that this region of *F. heparinum* chromosome imparts a negative-selective effect on *E. coli* cells that harbor it.

As in the case for isolation of the heparinase II gene, the PCR fragment was split in order to avoid the problem of foreign DNA toxicity. Digestion of the 981 bp *BamHI*-digested heparinase III PCR fragment with restriction endonuclease *ClaI* produced two fragments of 394 and 587 bp. The amplified *F. heparinum* region was treated with *ClaI* and the two fragments separated by agarose gel electrophoresis. The 587 and 394 base pair fragments were ligated separately into plasmid pBluescript that had been treated with restriction endonucleases *BamHI* and *ClaI*. In addition, the entire 981 bp PCR fragment was purified and ligated into *BamHI* cut pBluescript. The ligated plasmids were inserted into the XL-1 Blue *E. coli*. Transformants containing plasmids with inserts were selected on the basis of their ability to form white colonies on LB-agar plates containing X-gal, IPTG and 50 ug/ml ampicillin, as described by Maniatis. Plasmid pFB1 containing the 587 bp *F. heparinum* DNA fragment and plasmid pFB2 containing the entire 981 base pair fragment were isolated by this method. The XL-1 Blue strain, which, like strain FTB1, contains the *lac Iq* repressor

SUBSTITUTE SHEET (RULE 26)

gene on an F' episome, allowed for stable maintenance of the complete *BamHI* PCR fragment, unlike FTB1. The reason for this discrepancy is not apparent from the genotypes of the two strains (i.e., both are *rec A*, etc.).

DNA sequence analysis of the *F. heparinum* DNA in plasmid pFB1
5 showed that it contained a sequence encoding peptide Hep3-B while the *F. heparinum* insert in plasmid pFB2 contained a DNA sequence encoding peptides Hep3-D and Hep3-B, Figure 9. This analysis confirmed that these inserts were part of the gene encoding heparinase III.

The PCR fragment insert in plasmid pFB1 was labeled with ^{32}P -ATP
10 using a Random Primed DNA Labeling kit (Boehringer Mannheim, Laval, Quebec), and was used to screen the *F. heparinum* λ DASHII library, Figure 6, constructed as described herein. The lambda library was plated out to obtain approximately 1500 plaques, which were transferred to nitrocellulose filters (Schleicher & Schuel, Keene, NH). The PCR probe was
15 purified by ethanol precipitation. Plaque hybridization was carried out using the conditions described above. Eight positive lambda plaques were identified. Lambda DNA was isolated from lysed bacterial cultures as described in Maniatis and further analyzed by restriction analysis and by Southern blotting using a Hybond-N nylon membrane (Amersham Corporation, Arlington Heights, IL) following the protocol described in Maniatis. A 2.7 kilobase *HindIII* fragment from lambda plaque #3, which strongly hybridized to the PCR probe, was isolated and cloned in pBluescript, in the XL-1 Blue *E. coli* background, to yield plasmid pHindIIIBD, Figure 6. This clone was further analyzed by DNA sequencing.
20 The sequence data was obtained using successive nested deletions of pHindIIIBD generated with the Erase-a-Base System (Promega Corporation, Madison, WI) or sequenced using synthetic oligonucleotide primers.

Sequence analysis revealed a single continuous open reading frame, without a translational termination codon, of 1929 base pairs, corresponding to 643 amino acids. Further screening of the lambda library led to the identification of a 673 bp *KpnI* fragment which was similarly 5 cloned into the *KpnI* site of pBluescript, creating plasmid pFB4. The termination codon was found within the *KpnI* fragment adding an extra 51 base pairs to the heparinase III gene and an additional 16 amino acid to the heparinase III protein. The complete heparinase III gene was later found to be included within a 3.2 kilobase *PstI* fragment from lambda 10 plaque #118. The complete heparinase III gene from *Flavobacterium* is thus 1980 base pairs in length, Figure 8, and encodes a 659 amino acid protein, Figure 9. N-terminal amino acid sequencing of deblocked, processed heparinase III indicated that the mature protein begins with Q- 25, and contains 635 amino acids with a calculated molecular weight of 15 73,135 Daltons, Figure 9.

EXAMPLE 9: Expression of Heparinase III in *E. coli*

PCR was used to generate a mature, truncated heparinase III gene, which had 16 amino acids deleted from the carboxy-terminus of the 20 protein. An oligonucleotide comprised of 5'-CGCGGATCCATGCAAAGCT CTTCCATT-3' (SEQU ID NO:25) was designed to insert an ATG start site immediately preceding the codon for the first amino acid (Q-25) of mature heparinase III, while an oligonucleotide comprised of 5'-CGCGGATCCTCA AAGCTTGCCTTCTC-3' (SEQU ID NO:26), was designed to insert a 25 termination codon after the last amino acid of the heparinase III gene on the 2.7 kb *HindIII* fragment. Both oligonucleotides also contained a *BamHI* site. Plasmid p*HindIIIBD* was used as the template in a PCR reaction with an annealing temperature of 50°C. A specific fragment of the expected

size, 1857 base pairs, was obtained. This fragment encodes a protein of 620 amino acids with a calculated MW of 71,535 Da. It was isolated and inserted in the *BamHI* site of the expression vector pGB. This construct was named pGB-H3Δ3', Figure 7.

5 To add the missing 3' region of heparinase III, the *BspEI/SalI* restriction fragment from pGB-H3Δ3' was removed and replaced with the *BspEI/SalI* fragment from pFB5. The construct containing the complete heparinase III gene was named pGBH3, Figure 7. Recombinant heparinase III is a protein of 637 amino acids with a calculated molecular weight of
10 73,266 Daltons. *E. coli* strain XL-1 Blue(pGBH3) was grown at 37°C in LB medium containing 75 ug/ml kanamycin to an OD₆₀₀ of 0.5, at which point the tac promoter from pGB was induced by the addition of 1 mM IPTG. Cultures were grown an additional 2-5 hours at either 23° C, 30° C or 37° C. The cells were cooled on ice, concentrated by centrifugation and
15 resuspended in cold PBS at 1/10th the original culture volume. Cells were lysed by sonication and cell debris removed by centrifugation at 10,000 x g for 5 minutes. The pellet and supernatant fractions were analyzed for heparan sulfate degrading (heparinase III) activity. Heparan sulfate degrading activities of 1.29, 5.27 and 3.29 IU/ml were observed from
20 cultures grown at 23°, 30° and 37° C, respectively.

The present invention describes a methodology for obtaining highly purified heparin and heparan sulfate degrading proteins by expressing the genes for these proteins in a suitable expression system and applying the steps of cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography. Variations of these methods will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications are intended to come within the scope of the appended claims.

TABLE 1

Purification of heparinase enzymes from
Flavobacterium heparinum fermentations

sample	activity (IU)	specific activity (IU/mg)	yield (%)
fermentation			
heparin degrading	39,700	1.06	100
<u>heparan sulfate degrading</u>	75,400	ND	100
osmolate			
heparin degrading	15,749	ND	40
<u>heparan sulfate degrading</u>	42,000	ND	56
cation exchange			
heparin degrading	12,757	ND	32
<u>heparan sulfate degrading</u>	27,540	ND	37
cellufine sulfate			
heparin degrading	8,190	ND	21
<u>heparan sulfate degrading</u>	9,328	30.8	12
hydroxylapatite			
heparinase I	7,150	115.3	18
heparinase II	2,049	28.41	3
<u>heparinase III</u>	5,150	44.46	7

SUBSTITUTE SHEET (RULE 26)

TABLE 2

Properties of heparinases from
Flavobacterium heparinum

<u>sample</u>	<u>heparinase I</u>	<u>heparinase II</u>	<u>heparinase III</u>
<u>Km (μM)</u>	17.8	57.7	29.4
<u>Kcat (s⁻¹)</u>	157	23.3	164
<u>substrate specificity</u>	H	H and HS	HS
<u>N-terminal peptide</u>	QQKKSG	QTKADV	QSSSIT
<u>glycosylation</u>	yes	yes	maybe

H - heparin, HS - heparan sulfate

TABLE 3

Codon usage table for *Flavobacterium* and *Escherichia coli*

amino acid	codon(s)	consensus codon	
		<i>E. coli</i>	<i>Flavobacterium</i>
A	GCT, GCC, GCG, GCA	GCT	GCC
C	TGT, TGC	EITHER	EITHER
D	GAT, GAC	EITHER	EITHER
E	GAG, GAA	GAA	GAA
F	TTC, TTT	EITHER	TTT
G	GGC, GGA, GGG, GGT	GGC or GGT	GGC
H	CAC, CAT	CAT	CAT
I	ATC, ATA, ATT	ATA	ATC
K	AAA, AAG	AAA	AAA
L	CTT, CTA, CTG, TTG, TTA, CTC	CTG	CTG
M	ATG	ATG	ATG
N	AAC, AAT	AAC	AAT
P	CCC, CCT, CCA, CCG	CCG	CCG
Q	CAG, CAA	CAG	CAG
R	CGT, AGA, CGC, CGA, AGG, CGG	CGT	CGC
S	TCA, TCC, TCG, TCT, AGC, AGT	TCT	?
T	ACG, ACC, ACT, ACA	ACC or ACT	ACC or ACA
V	GTC, GTA, GTT, GTG	GTT	?
W	TGG	TGG	TGG
Y	TAC, TAT	EITHER	TAT

SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT(s): IBEX TECHNOLOGIES and
ZIMMERMANN, Joseph
- (ii) TITLE OF INVENTION: Nucleic Acid Sequences And Expression
Systems For Heparinase II And Heparinase III Derived From
Flavobacterium heparinum

(iii) NUMBER OF SEQUENCES: 26

- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Hale and Dorr
 - (B) STREET: 1455 Pennsylvania Avenue, N.W.
 - (C) CITY: Washington, D.C.
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 20004

- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/US95/07391
 - (B) FILING DATE: 09-JUNE-1995
 - (C) CLASSIFICATION:

- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/258,639
 - (B) FILING DATE: 10 JUNE 1994

- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: BAKER, Hollie L.
 - (B) REGISTRATION NUMBER: 31,321
 - (C) REFERENCE/DOCKET NUMBER: 104385.116PCT

- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (202) 942-8400
 - (B) TELEFAX: (202) 942-8484

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2339 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGAAAAGAC AATTATAACCT GTATGTGATT TTTGTTGTAG TTGAACTTAT GGTTTTTACA

60

ACAAAGGGCT ATTCCCAAAC CAAGGCCGAT GTGGTTTGGGA AAGACGTGGA TGGCGTATCT	120
ATGCCCATAC CCCCTAAGAC CCACCCGCGT TTGTATCTAC GTGAGCAGCA AGTCCTGAC	180
CTGAAAAACA GGATGAACGA CCCTAAACTG AAAAAAGTTT GGGCCGATAT GATCAAGATG	240
CAGGAAGACT GGAAGCCAGC TGATATTCT GAAGTTAAAG ACTTTCGTTT TTATTTAAC	300
CAGAAAGGGC TTACTGTAAG GGTTGAACTA ATGCCCTGA ACTATCTGAT GACCAAGGAT	360
CCAAAGGTAG GACGGGAAGC CATCACTTCA ATTATTGATA CCCTTGAAAC TGCAACTTTT	420
AAACCAGCAG GTGATATTTC GAGAGGGATA GTGATATTTC GAGAGGGATA GGCTGTTTA	480
TGGTTACAGG GGCCATTGTG TATGACTGGT GCTACGATCA GCTGAAACCA GAAGAGAAAA	540
CACGTTTGT GAAGGCATT GTGAGGCTGG CCAAAATGCT CGAATGTGGT TATCCTCCGG	600
TAAAAGACAA GTCTATTGTT GGGCATGCTT CCGAATGGAT GATCATGCGG GACCTGCTTT	660
CTGTAGGGAT TGCCATTAC GATGAATTCC CTGAGATGTA TAACCTGGCT GCGGGTCGTT	720
TTTTCAAAGA ACACCTGGTT GCCCGCAACT GGTTTATCC CTCGCATAAC TACCATCAGG	780
GTATGTCATA CCTGAACGTA AGATTTACCA ACGACCTTT TGCCCTCTGG ATATTAGACC	840
GGATGGGCGC TGGTAATGTG TTTAATCCAG GGCAGCAGTT TATCCTTTAT GACCGATCT	900
ATAAACGCCG CCCCAGTGGA CAGATTTAG CAGGTGGAGA TGTAGATTAT TCCAGGAAAA	960
AACCAAAATA TTATACGATG CCTGCATTGC TTGCAGGTAG CTATTATAA GATGAATACC	1020
TTAATTACGA ATTCTGAAA GATCCAATG TTGAGCCACA TTGCAAATTG TTGAAATT	1080
TATGGCGCGA TACCCAGTTG GGAAGTCGTA AGCCTGATGA TTTGCCACTT TCCAGGTACT	1140
CAGGATCGCC TTTTGGATGG ATGATTGCCG GTACCGGATG GGGTCCGGAA AGTGTGATTG	1200
CAGAGATGAA AGTCAACGAA TATTCTTTC TTAACCATCA GCATCAGGAT GCAGGAGCCT	1260
TCCAGATCTA TTACAAAGGC CCGCTGGCCA TAGATGCAGG CTCGTATACA GGTTCTTCAG	1320
GAGGTTATAA CAGTCCGCAC ACAAGAACT TTTTTAAGCG GACTATTGCA CACAATAGCT	1380
TGCTGATTAA CGATCCTAAA GAAACTTCA GTTCGTCGGG ATATGGTGGA AGTGACCATA	1440
CCGATTTCGC TGCCAACGAT GGTGGTCAGC GGCTGCCGG AAAAGGTTGG ATTGCACCCC	1500
GCGACCTTAA AGAAATGCTG GCAGGCGATT TCAGGACCGG CAAAATTCTT GCCCAGGGCT	1560
TTGGTCCGGGA TAACCAAACC CCTGATTATA CTTATCTGAA AGGAGACATT ACAGCAGCTT	1620
ATTGGCAAA AGTGAAGGAA GTAAAACGTT CATTCTTATT CCTGAACCTT AAGGATGCCA	1680
AAGTTCCGGC AGCGATGATC GTTTTGACA AGGTAGTTGC TTCCAATCCT GATTTTAAGA	1740
AGTTCTGGTT GTTGCACAGT ATTGAGCAGC CTGAAATAA GGGGAATCAG ATTACCATAA	1800
AACGTACAAA AAACGGTGAT AGTGGGATGT TGGTGAATAC GGCTTGCTG CCGGATGCGG	1860
CCAATTCAAA CATTACCTCC ATTGGCGGCA AGGGCAAAGA CTTCTGGGTG TTTGGTACCA	1920

SUBSTITUTE SHEET (RULE 26)

ATTATACCAA TGATCCTAAA CCGGGCACGG ATGAAGCATT GGAACGTGGA GAATGGCGTG	1980
TGGAAATCAC TCCAAAAAAG GCAGCAGCCG AAGATTACTA CCTGAATGTG ATACAGATTG	2040
CCGACAATAC ACAGCAAAAA TTACACGAGG TGAAGCGTAT TGACGGTGAC AAGGTTGTTG	2100
GTGTGCAGCT TGCTGACAGG ATAGTTACTT TTAGCAAAAC TTCAGAAACT GTTGATCGTC	2160
CCTTTGGCTT TTCCGTTGTT GGTAAAGGAA CATTCAAATT TGTGATGACC GATCTTTAG	2220
CGGGTACCTG GCAGGTGCTG AAAGACGGAA AAATACTTTA TCCTGCGCTT TCTGCAAAAG	2280
GTGATGATGG ACCCCTTTAT TTTGAAGGAA CTGAAGGAAC CTACCGTTTT TTGAGATAA	

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 772 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Lys	Arg	Gln	Leu	Tyr	Leu	Tyr	Val	Ile	Phe	Val	Val	Val	Glu	Leu
1				5					10					15	
Met	Val	Phe	Thr	Thr	Lys	Gly	Tyr	Ser	Gln	Thr	Lys	Ala	Asp	Val	Val
				20				25				30			
Trp	Lys	Asp	Val	Asp	Gly	Val	Ser	Met	Pro	Ile	Pro	Pro	Lys	Thr	His
				35			40				45				
Pro	Arg	Leu	Tyr	Leu	Arg	Glu	Gln	Gln	Val	Pro	Asp	Leu	Lys	Asn	Arg
				50		55				60					
Met	Asn	Asp	Pro	Lys	Leu	Lys	Lys	Val	Trp	Ala	Asp	Met	Ile	Lys	Met
				65		70			75				80		
Gln	Glu	Asp	Trp	Lys	Pro	Ala	Asp	Ile	Pro	Glu	Val	Lys	Asp	Phe	Arg
				85				90				95			
Phe	Tyr	Phe	Asn	Gln	Lys	Gly	Leu	Thr	Val	Arg	Val	Glu	Leu	Met	Ala
				100				105				110			
Leu	Asn	Tyr	Leu	Met	Thr	Lys	Asp	Pro	Lys	Val	Gly	Arg	Glu	Ala	Ile
				115			120				125				
Thr	Ser	Ile	Ile	Asp	Thr	Leu	Glu	Thr	Ala	Thr	Phe	Lys	Pro	Ala	Gly
				130		135				140					
Asp	Ile	Ser	Arg	Gly	Ile	Gly	Leu	Phe	Met	Val	Thr	Gly	Ala	Ile	Val
				145		150			155			160			
Tyr	Asp	Trp	Cys	Tyr	Asp	Gln	Leu	Lys	Pro	Glu	Glu	Lys	Thr	Arg	Phe
				165				170				175			

Val Lys Ala Phe Val Arg Leu Ala Lys Met Leu Glu Cys Gly Tyr Pro
 180 185 190
 Pro Val Lys Asp Lys Ser Ile Val Gly His Ala Ser Glu Trp Met Ile
 195 200 205
 Met Arg Asp Leu Leu Ser Val Gly Ile Ala Ile Tyr Asp Glu Phe Pro
 210 215 220
 Glu Met Tyr Asn Leu Ala Ala Gly Arg Phe Phe Lys Glu His Leu Val
 225 230 235 240
 Ala Arg Asn Trp Phe Tyr Pro Ser His Asn Tyr His Gln Gly Met Ser
 245 250 255
 Tyr Leu Asn Val Arg Phe Thr Asn Asp Leu Phe Ala Leu Trp Ile Leu
 260 265 270
 Asp Arg Met Gly Ala Gly Asn Val Phe Asn Pro Gly Gln Gln Phe Ile
 275 280 285
 Leu Tyr Asp Ala Ile Tyr Lys Arg Arg Pro Asp Gly Gln Ile Leu Ala
 290 295 300
 Gly Gly Asp Val Asp Tyr Ser Arg Lys Lys Pro Lys Tyr Tyr Thr Met
 305 310 315 320
 Pro Ala Leu Leu Ala Gly Ser Tyr Tyr Lys Asp Glu Tyr Leu Asn Tyr
 325 330 335
 Glu Phe Leu Lys Asp Pro Asn Val Glu Pro His Cys Lys Leu Phe Glu
 340 345 350
 Phe Leu Trp Arg Asp Thr Gln Leu Gly Ser Arg Lys Pro Asp Asp Leu
 355 360 365
 Pro Leu Ser Arg Tyr Ser Gly Ser Pro Phe Gly Trp Met Ile Ala Arg
 370 375 380
 Thr Gly Trp Gly Pro Glu Ser Val Ile Ala Glu Met Lys Val Asn Glu
 385 390 395 400
 Tyr Ser Phe Leu Asn His Gln His Gln Asp Ala Gly Ala Phe Gln Ile
 405 410 415
 Tyr Tyr Lys Gly Pro Leu Ala Ile Asp Ala Gly Ser Tyr Thr Gly Ser
 420 425 430
 Ser Gly Gly Tyr Asn Ser Pro His Asn Lys Asn Phe Phe Lys Arg Thr
 435 440 445
 Ile Ala His Asn Ser Leu Leu Ile Tyr Asp Pro Lys Glu Thr Phe Ser
 450 455 460
 Ser Ser Gly Tyr Gly Gly Ser Asp His Thr Asp Phe Ala Ala Asn Asp
 465 470 475 480
 Gly Gly Gln Arg Leu Pro Gly Lys Gly Trp Ile Ala Pro Arg Asp Leu
 485 490 495
 Lys Glu Met Leu Ala Gly Asp Phe Arg Thr Gly Lys Ile Leu Ala Gln
 500 505 510

SUBSTITUTE SHEET (RULE 26)

45

Gly Phe Gly Pro Asp Asn Gln Thr Pro Asp Tyr Thr Tyr Leu Lys Gly
 515 520 525

Asp Ile Thr Ala Ala Tyr Ser Ala Lys Val Lys Glu Val Lys Arg Ser
 530 535 540

Phe Leu Phe Leu Asn Leu Lys Asp Ala Lys Val Pro Ala Ala Met Ile
 545 550 555 560

Val Phe Asp Lys Val Val Ala Ser Asn Pro Asp Phe Lys Lys Phe Trp
 565 570 575

Leu Leu His Ser Ile Glu Gln Pro Glu Ile Lys Gly Asn Gln Ile Thr
 580 585 590

Ile Lys Arg Thr Lys Asn Gly Asp Ser Gly Met Leu Val Asn Thr Ala
 595 600 605

Leu Leu Pro Asp Ala Ala Asn Ser Asn Ile Thr Ser Ile Gly Gly Lys
 610 615 620

Gly Lys Asp Phe Trp Val Phe Gly Thr Asn Tyr Thr Asn Asp Pro Lys
 625 630 635 640

Pro Gly Thr Asp Glu Ala Leu Glu Arg Gly Glu Trp Arg Val Glu Ile
 645 650 655

Thr Pro Lys Lys Ala Ala Ala Glu Asp Tyr Tyr Leu Asn Val Ile Gln
 660 665 670

Ile Ala Asp Asn Thr Gln Gln Lys Leu His Glu Val Lys Arg Ile Asp
 675 680 685

Gly Asp Lys Val Val Gly Val Gln Leu Ala Asp Arg Ile Val Thr Phe
 690 695 700

Ser Lys Thr Ser Glu Thr Val Asp Arg Pro Phe Gly Phe Ser Val Val
 705 710 715 720

Gly Lys Gly Thr Phe Lys Phe Val Met Thr Asp Leu Leu Ala Gly Ile
 725 730 735

Trp Gln Val Leu Lys Asp Gly Lys Ile Leu Tyr Pro Ala Leu Ser Ala
 740 745 750

Lys Gly Asp Asp Gly Pro Leu Tyr Phe Glu Gly Thr Glu Gly Thr Tyr
 755 760 765

Arg Phe Leu Arg
 770

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1980 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGACTACGA AAATTTTAA AAGGATCATT GTATTGCTG TAATTGCCCT	50
ATCGTCGGGA AATATACTTG CACAAAGCTC TTCCATTACC AGGAAAGATT	100
TTGACCACAT CAACCTTGAG TATTCCGGAC TGGAAAAGGT TAATAAAGCA	150
GTTGCTGCCG GCAACTATGA CGATGCGGCC AAAGCATTAC TGGCATACTA	200
CAGGGAAAAA AGTAAGGCCA GGGAACCTGA TTTCAGTAAT GCAGAAAAGC	250
CTGCCGATAT ACGCCAGCCC ATAGATAAGG TTACGCGTGA AATGGCCGAC	300
AAGGCTTGG TCCACCAGTT TCAACCGCAC AAAGGCTACG GCTATTTGA	350
TTATGGTAAA GACATCAACT GGCAGATGTG GCCGGTAAAA GACAATGAAG	400
TACGCTGGCA GTTGCACCGT GTAAAATGGT GGCAGGCTAT GGCCCTGGTT	450
TATCACGCTA CGGGCGATGA AAAATATGCA AGAGAATGGG TATATCAGTA	500
CAGCGATTGG GCCAGAAAAA ACCCATTGGG CCTGTCGCAG GATAATGATA	550
AATTTGTGTG GCGGCCCTT GAAGTGTGG ACAGGGTACA AAGTCTTCCC	600
CCAACCTTCA GCTTATTTGT AAAACTGCCA GCCTTACCC CAGCCTTTT	650
AATGGAATTT TTAAACAGTT ACCACCAACA GGCGATTAT TTATCTACGC	700
ATTATGCCGA ACAGGGAAAC CACCGTTTAT TTGAAGGCCA ACGCAACTTG	750
TTTGCAGGGG TATCTTCCC TGAATTAAA GATTACCAA GATGGAGGCA	800
AACCGGCATA TCGGTGCTGA ACACCGAGAT CAAAAAACAG GTTTATGCCG	850
ATGGGATGCA GTTGAACTT TCACCAATT ACCATGTAGC TGCCATCGAT	900
ATCTTCTTAA AGGCCTATGG TTCTGCAAAA CGAGTTAACCG TTGAAAAAGA	950
ATTTCCGCAA TCTTATGTAC AAAACTGTAGA AAATATGATT ATGGCGCTGA	1000
TCAGTATTTCA ACTGCCAGAT TATAACACCC CTATGTTGG AGATTCATGG	1050
ATTACAGATA AAAATTCAG GATGGCACAG TTTGCCAGCT GGGCCCGGGT	1100
TTTCCCGGCA AACCAAGGCCA TAAAATATTT TGCTACAGAT GGCAAACAAG	1150
GTAAGGCGCC TAACTTTTA TCCAAAGCAT TGAGCAATGC AGGCTTTAT	1200
ACGTTTAGAA GCGGATGGGA TAAAATGCA ACCGTTATGG TATTAAAAGC	1250
CAGTCCTCCC GGGGAATTTC ATGCCAGCC GGATAACGGG ACTTTGAAC	1300
TTTTTATAAA GGGCAGAAAC TTTACCCAG ACGCCGGGGT ATTTGTGTAT	1350
AGCGGCGACG AAGCCATCAT GAAACTGCGG AACTGGTACC GTCAAACCCG	1400
CATACACAGC ACGCTTACAC TCGACAATCA AAATATGGTC ATTACCAAAG	1450

CCCGGCAAAA CAAATGGGAA ACAGGAAATA ACCTTGATGT GCTTACCTAT	1500
ACCAACCCAA CCTATCCGAA TCTGGACCAT CAGCGCAGTG TACTTTCAT	1550
CAACAAAAAA TACTTTCTGG TCATCGATAG GGCAATAGGC GAAGCTACCG	1600
GAAACCTGGG CGTACACTGG CAGCTTAAAG AAGACAGCAA CCCTGTTTC	1650
GATAAGACAA AGAACCGGGT TTACACCACT TACAGAGATG GTAACAACCT	1700
GATGATCCAA TCGTTGAATG CGGACAGGAC CAGCCTCAAT GAAGAAGAAG	1750
GAAAGGTATC TTATGTTTAC AATAAGGAGC TGAAAAGACC TGCTTCGTA	1800
TTTGAAAAGC CTAAAAAGAA TGCCGGCACA CAAAATTTG TCAGTATAGT	1850
TTATCCATAC GACGGCCAGA AGGCTCCAGA GATCAGCATA CGGGAAAACA	1900
AGGGCAATGA TTTTGAGAAA GGCAAGCTTA ATCTAACCTT TACCATTAAC	1950
GGAAAACAAC AGCTTGTGTT GGTCCTTAG	1980

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 659 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Thr Thr Lys Ile Phe Lys Arg Ile Ile Val Phe Ala Val Ile Ala			
1	5	10	15
Leu Ser Ser Gly Asn Ile Leu Ala Gln Ser Ser Ser Ile Thr Arg Lys			
20	25	30	
Asp Phe Asp His Ile Asn Leu Glu Tyr Ser Gly Leu Glu Lys Val Asn			
35	40	45	
Lys Ala Val Ala Ala Gly Asn Tyr Asp Asp Ala Ala Lys Ala Leu Leu			
50	55	60	
Ala Tyr Tyr Arg Glu Lys Ser Lys Ala Arg Glu Pro Asp Phe Ser Asn			
65	70	75	80
Ala Glu Lys Pro Ala Asp Ile Arg Gln Pro Ile Asp Lys Val Thr Arg			
85	90	95	
Glu Met Ala Asp Lys Ala Leu Val His Gln Phe Gln Pro His Lys Gly			
100	105	110	
Tyr Gly Tyr Phe Asp Tyr Gly Lys Asp Ile Asn Trp Gln Met Trp Pro			

115	120	125
Val Lys Asp Asn Glu Val Arg Trp Gln Leu His Arg Val Lys Trp Trp		
130	135	140
Gln Ala Met Ala Leu Val Tyr His Ala Thr Gly Asp Glu Lys Tyr Ala		
145	150	155
160		
Arg Glu Trp Val Tyr Gln Tyr Ser Asp Trp Ala Arg Lys Asn Pro Leu		
165	170	175
Gly Leu Ser Gln Asp Asn Asp Lys Phe Val Trp Arg Pro Leu Glu Val		
180	185	190
Ser Asp Arg Val Gln Ser Leu Pro Pro Thr Phe Ser Leu Phe Val Asn		
195	200	205
Ser Pro Ala Phe Thr Pro Ala Phe Leu Met Glu Phe Leu Asn Ser Tyr		
210	215	220
His Gln Gln Ala Asp Tyr Leu Ser Thr His Tyr Ala Glu Gln Gly Asn		
225	230	235
240		
His Arg Leu Phe Glu Ala Gln Arg Asn Leu Phe Ala Gly Val Ser Phe		
245	250	255
Pro Glu Phe Lys Asp Ser Pro Arg Trp Arg Gln Thr Gly Ile Ser Val		
260	265	270
Leu Asn Thr Glu Ile Lys Lys Gln Val Tyr Ala Asp Gly Met Gln Phe		
275	280	285
Glu Leu Ser Pro Ile Tyr His Val Ala Ala Ile Asp Ile Phe Leu Lys		
290	295	300
Ala Tyr Gly Ser Ala Lys Arg Val Asn Leu Glu Lys Glu Phe Pro Gln		
305	310	315
320		
Ser Tyr Val Gln Thr Val Glu Asn Met Ile Met Ala Leu Ile Ser Ile		
325	330	335
Ser Leu Pro Asp Tyr Asn Thr Pro Met Phe Gly Asp Ser Trp Ile Thr		
340	345	350
Asp Lys Asn Phe Arg Met Ala Gln Phe Ala Ser Trp Ala Arg Val Phe		
355	360	365
Pro Ala Asn Gln Ala Ile Lys Tyr Phe Ala Thr Asp Gly Lys Gln Gly		
370	375	380
Lys Ala Pro Asn Phe Leu Ser Lys Ala Leu Ser Asn Ala Gly Phe Tyr		
385	390	395
400		
Thr Phe Arg Ser Gly Trp Asp Lys Asn Ala Thr Val Met Val Leu Lys		
405	410	415
Ala Ser Pro Pro Gly Glu Phe His Ala Gln Pro Asp Asn Gly Thr Phe		
420	425	430
Glu Leu Phe Ile Lys Gly Arg Asn Phe Thr Pro Asp Ala Gly Val Phe		
435	440	445

SUBSTITUTE SHEET (RULE 26)

49

Val Tyr Ser Gly Asp Glu Ala Ile Met Lys Leu Arg Asn Trp Tyr Arg
 450 455 460

Gln Thr Arg Ile His Ser Thr Leu Thr Leu Asp Asn Gln Asn Met Val
 465 470 475 480

Ile Thr Lys Ala Arg Gln Asn Lys Trp Glu Thr Gly Asn Asn Leu Asp
 485 490 495

Val Leu Thr Tyr Thr Asn Pro Ser Tyr Pro Asn Leu Asp His Gln Arg
 500 505 510

Ser Val Leu Phe Ile Asn Lys Lys Tyr Phe Leu Val Ile Asp Arg Ala
 515 520 525

Ile Gly Glu Ala Thr Gly Asn Leu Gly Val His Trp Gln Leu Lys Glu
 530 535 540

Asp Ser Asn Pro Val Phe Asp Lys Thr Lys Asn Arg Val Tyr Thr Thr
 545 550 555 560

Tyr Arg Asp Gly Asn Asn Leu Met Ile Gln Ser Leu Asn Ala Asp Arg
 565 570 575

Thr Ser Leu Asn Glu Glu Gly Lys Val Ser Tyr Val Tyr Asn Lys
 580 585 590

Glu Leu Lys Arg Pro Ala Phe Val Phe Glu Lys Pro Lys Lys Asn Ala
 595 600 605

Gly Thr Gln Asn Phe Val Ser Ile Val Tyr Pro Tyr Asp Gly Gln Lys
 610 615 620

Ala Pro Glu Ile Ser Ile Arg Glu Asn Lys Gly Asn Asp Phe Glu Lys
 625 630 635 640

Gly Lys Leu Asn Leu Thr Leu Thr Ile Asn Gly Lys Gln Gln Leu Val
 645 650 655

Leu Val Pro

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Glu Phe Pro Glu Met Tyr Asn Leu Ala Ala Gly Arg
 1 5 10

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids

50

- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Lys Pro Ala Asp Ile Pro Glu Val Lys Asp Gly Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Leu Ala Gly Asp Phe Val Thr Gly Lys Ile Leu Ala Gln Gly Phe Gly
1 5 10 15
Pro Asp Asn Gln Thr Pro Asp Tyr Thr Tyr Leu
20 25

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Leu Ile Lys Asn Glu Val Arg Trp Gln Leu His Arg Val Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Val Leu Lys Ala Ser Pro Pro Gly Glu Phe His Ala Gln Pro Asp Asn
1 5 10 15

SUBSTITUTE SHEET (RULE 26)

51

Gly Thr Phe Glu Leu Phe Ile
20

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Lys Ala Leu Val His Trp Phe Trp Pro His Lys Gly Tyr Gly Tyr Phe
1 5 10 15

Asp Tyr Gly Lys Asp Ile Asn
20

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GAATTCCCTG AGATGTACAA TCTGGCCGC

29

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCGGCAGCCA GATTGTACAT TTCAGG

26

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAACCCGCCG ACATTCGG AGTAAAAGA

29

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CGAAAGTCTT TTACTTCGGG AATGTCGGC

29

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TGAGGATTCA TGCAAACCAA GGCGATGTG GTTTGGAA

38

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGAGGATAAC CACATTCGAG CATT

24

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double

SUBSTITUTE SHEET (RULE 26)

53

- (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GAATTCCATC AGTTTCAGCC GCATAAA

27

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GAATTCTTTA TGC GGCTGAA ACTGATG

27

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GAATTCCCGC CGGGCGAATT TCATGC

26

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GAATTCGAT GAAATTGCGCC CGGC

26

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GGGAATTC GATGCCAGCC GAAATGGAC

29

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GTCCATTTCG GCTGGGCATG AAATTCCC

28

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GTCATCAGTT CAGCCCATAA AGGTATGG

28

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CCCATACCTT ATGGGCTGAA CTGATGAC

28

(2) INFORMATION FOR SEQ ID NO:25:

SUBSTITUTE SHEET (RULE 26)

55

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CGCGGATCCA TGCAAAGCTC TTCCATT

27

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CGCGGATCCT CAAAGCTTGC CTTTCTC

27

We claim:

1. A recombinant nucleic acid sequence which encodes heparinase II from *Flavobacterium heparinum*.
2. The nucleic acid sequence of claim 1 comprising the sequence of SEQU ID NO:1.
3. The nucleic acid sequence of claim 1 further comprising a nucleic acid sequence capable of directing the expression of said heparinase.
4. The nucleic acid sequence of claim 3 comprising a modified ribosome binding region.
5. A host cell transformed with a vector comprising the nucleic acid sequence of claim 3, said host cell being capable of heparinase II.
6. The host cell of claim 5, wherein said host cell is *E. coli*.
7. A recombinant nucleic acid sequence which encodes heparinase III from *Flavobacterium heparinum*.
8. The nucleic acid sequence of claim 7 comprising the sequence of SEQU ID NO:3.
9. The nucleic acid sequence of claim 7 further comprising a nucleic acid sequence capable of directing the expression of said heparinase.

SUBSTITUTE SHEET (RULE 26)

10. The nucleic acid sequence of claim 9 comprising a modified ribosome binding region.
11. A host cell transformed with a vector comprising the nucleic acid sequence of claim 9, said host cell being capable of expressing heparinase III.
12. The host cell of claim 11, wherein said host cell is *E. coli*.
13. Isolated, recombinant heparinase II in substantially pure form.
14. The heparinase II of claim 13 comprising the amino acid sequence of SEQUID NO:2.
15. Isolated, recombinant heparinase III in substantially pure form.
16. The heparinase III of claim 15 comprising the amino acid sequence of SEQUID NO:4.
17. An expression vector for the expression of heparinases comprising a modified ribosome binding region containing a Shine-Dalgarno sequence, a spacer region between the Shine-Dalgarno sequence and the ATG start codon, and a recombinant nucleotide sequence encoding heparinase I, II or III.
18. The expression vector of claim 17 wherein the Shine-Dalgarno sequence is 5 base pairs in length.

19. The expression vector of claim 17 wherein the spacer region between the Shine-Dalgarno sequence and the ATG start codon is 9 base pairs in length.
20. A method of expressing genes from *Flavobacterium* species comprising constructing the expression vector of claim 17 and transforming a prokaryote host cell with said expression vector.
21. The method of claim 20 wherein said expression vector encodes heparinase I.
22. The method of claim 20 wherein said expression vector encodes heparinase II.
23. The method of claim 20 wherein said expression vector encodes heparinase III.
24. An antibody isolated from animals injected with a heparinase from *F. heparinum* which are specific for the amino acid sequences of the heparinase.
25. The antibody of claim 24 wherein said heparinase is heparinase I.
26. The antibody of claim 24 wherein said heparinase is heparinase II.
27. The antibody of claim 24 wherein said heparinase is heparinase III.

SUBSTITUTE SHEET (RULE 26)

28. An antibody isolated from animals injected with a heparinase which is specific for non-amino acid moieties of post-translationally modified *F. heparinum* proteins.

29. The polyclonal antibody of claim 28 wherein said heparinase is heparinase I.

30. The polyclonal antibody of claim 28 wherein said heparinase is heparinase II.

31. The polyclonal antibody of claim 28 wherein said heparinase is heparinase III.

32. A method of purifying heparinases from *Flavobacterium heparinum* comprising the steps of culturing *F. heparinum* cells, disrupting the cells, and performing cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography.

1/11

pBhep AGGAAACAGAATTCATG

S-D 10nt

pGhep AGGAGACAGAATTCATG

S-D 9nt

p Δ 4hep AGGAGAATTCATG

S-D 5 nt

pGB AGGAGACAGGATCC

S-D *BamHI*

FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/11




FIG.2

SUBSTITUTE SHEET (RULE 26)

3/11




FIG.3
SUBSTITUTE SHEET (RULE 26)

4/11

ATGAAAAGAC AATTATAACCT GTATGTGATT TTTGTTGTAG TTGAACTTAT GGTTTTACA	60
ACAAAGGGCT ATTCCCAAAC CAAGGCCGAT GTGCTTGGA AAGACGTGGA TGGCGTATCT	120
ATGCCCATAC CCCCTAACAGAC CCACCCCCGT TTGTATCTAC GTGAGCAGCA AGTTCTGAC	180
CTGAAAAACA GGATGAACGA CCCTAAACTG AAAAAAGTTT GGGCCGATAT GATCAAGATG	240
CAGGAAGACT GGAAGCCAGC TGATATTCT GAAGTTAAAG ACTTTCGTTT TTATTTAAC	300
CAGAAAGGGC TTACTGTAAG GGTTGAACTA ATGGCCCTGA ACTATCTGAT GACCAAGGAT	360
CCAAAGGTAG GACGGGAAGC CATCACTTCA ATTATTGATA CCCTGAAAC TCCAACTTT	420
AAACCAGCAG GTGATATTTC GAGAGGGATA GCCCTGTTA TCGTTACAGG GGCCATTG	480
TATCACTGCT GCTACGATCA GCTGAAACCA GAAGAGAAAA CACGTTTGT GAAGGCATT	540
GTGAGGCTGG CCAAAATGCT CGAATGTGGT TATCCTCCGG TAAAAGACAA GTCTATTGTT	600
GGGCATGCTT CCGAATGGAT GATCATGGGG GACCTGCTTT CTGTAGGGAT TCCCATTAC	660
GATGAATTCC CTGAGATGTA TAACCTGGCT GCGGGTCGTT TTTCAAAGA ACACCTGGTT	720
GCCCCCAACT GGTTTATCC CTCGCATAAC TACCATCAGG GTATGTCATA CCTGAACGTA	780
AGATTACCA ACCACCTTT TGCCCTCTGG ATATTAGACC GGATGGCGC TGGTAATGTG	840
TTTAATCCAG GGCAGCAGTT TATCCTTAT GACCCGATCT ATAAACGCCG CCCCCGATGGA	900
CAGATTTAG CAGGTGGAGA TGTAGATTAT TCCAGGAAAA AACCAAAATA TTATACGATG	960
CCTGCATTGC TTGCAGGTAG CTATTATAAA GATGAATACC TTAATTACGA ATTCTGAAA	1020
GATCCAATG TTGAGCCACA TTGCAAATTG TTCGAATTTC TATGGCGCGA TACCCAGTTG	1080
GGAAACTCGTA AGCCTGATGA TTTCCCACCT TCCAGGTACT CAGGATCGCC TTTTGGATGG	1140
ATGATTGCCG GTACCGGATG GGGTCCGGAA ACTGTGATTG CAGAGATGAA ACTCAACGAA	1200

FIG.4A

5/11

TATTCCCTTC TTAACCATCA GCATCAGGAT GCAGGAGCCT TCCAGATCTA TTACAAAGGC	1260
CCGCTGGCCA TAGATGCAGG CTCGTATACA GGTTCTTCAG GAGGTTATAA CAGTCCGCAC	1320
AACAAGAACT TTTTAAGCG GACTATTGCA CACAATAGCT TGCTGATTAA CGATCCTAAA	1380
GAAACTTTCA GTTCGTCGGG ATATGGTGA AGTGACCATA CCGATTTGC TGCCAACGAT	1440
GGTGGTCAGC GGCTGCCCGG AAAAGTTGG ATTGCACCCC GCGACCTTAA AGAAATGCTG	1500
GCAGGGCATT TCAGGACCGC CAAAATTCTT GCCCAGGGCT TTGGTCCCGA TAACCAAACC	1560
CCTGATTATA CTTATCTGAA AGGAGACATT ACAGCAGCTT ATTGGCAAA AGTGAAGGAA	1620
GTAAAACGTT CATTCTATT CCTGAACCTT AAGGATGCCA AAGTTCCGGC AGCGATGATC	1680
GTTTTGACA AGGTAGTTGC TTCCAATCCT GATTTAAGA AGTTCTGGTT GTGACAGT	1740
ATTGAGCAGC CTGAAATAAA GGGGAATCAG ATTACCATAA AACGTACAAA AAACGGTGAT	1800
AGTGGATGT TGGTGAATAC GGCTTGCTG CCGGATGCCG CCAATTCAA CATTACCTCC	1860
ATTGGCGGCA AGGGCAAAGA CTTCTGGTG TTTGGTACCA ATTATACCAA TGATCCTAAA	1920
CCGGGCACGG ATGAAGCATT GGAACGTGGA GAATGGCGTG TCGAAATCAC TCCAAAAAAG	1980
GCAGCAGCCG AAGATTACTA CCTGAATGTC ATACAGATTG CCGACAATAC ACAGAAAAAA	2040
TTACACGAGG TGAAGCGTAT TGACGGTGAC AACGTTGTTG GTGTGCAGCT TGCTGACAGG	2100
ATAGTTACTT TTAGCAAAAC TTCAGAAACT GTTGATGTC CCTTTGGCTT TTCCGTTGTT	2160
GGTAAAGGAA CATTCAAATT TGTGATGACC GATCTTTAG CGGGTACCTG GCAGGTGCTG	2220
AAAGACGGAA AAATACTTTA TCCTGCGCTT TCTGCAAAG GTGATGATGG ACCCCTTTAT	2280
TTTGAAGGAA CTGAAGGAAC CTACCGTTT TTGAGATAA	2319

FIG.4B

SUBSTITUTE SHEET (RULE 26)

6/11

MKRQLYLYVI FVVELMVFT TKGYSQTKAD VVVKDVGVS MPIPPKTHPR LYLREQQVPD

KPADIP EVKDFR
LKNRMNDPKL KKWDADMIMK QEDWKPADIP EVKDFRFYFN QKGLTVRVEL MALNYLMTKD
PEPTIDE 2B

PKVGREATS IIDLETATF KPAGDISRGIGLFMTGAIY YDWCYDQLKP EEKTRFVKAF

EFPEMYNLA AGR
VRLAKMLECG YPPVKDKSIV GHASEWMIMR DLLSGVIAIY DEFPEMYNLA AGRFFKEHLV
PEPTIDE 2A

ARNWFYP SHN YHQGMSYLN RFTNDLFALW ILDRMGAGNV FNPGQQFILY DAIYKRRPDG
QILAGGDVDY SRKKPKYYTM PALLAGSYYK DEYLNYEFLK DPNVEPHCKL FEFLWRDTQL
GSRKPDDPL SRYSGSPFGW MIARTGWCPE SVIAEMKVNE YSFLNHQHQD AGAFQIYYKG
PLAIDACSYT CSSCGYNSPH NKNFFKRTIA HNSLLIYDPK ETFSSSCYGG SDHTDFAAND

L AGDFVTGKIL AQGFGPDNQT PDYTYL
GGQRLPGKGW IAPRDLKEML AGDFRTGKIL AQGFGPDNQT PDYTYLKDI TAAYSAKVKE
PEPTIDE 2C

VKRSFLFLNL KDAKVPAA MI VFDKVVASNP DFKKFWLLHS IEQPEIKGNQ ITIKRTKNGD
SGMLVNTALL PDAANSNITS IGGKGKDFWW FGTNYTN DPK PGTDEALERG EWRVETTPKK
AAAEDYYLNV IQIADNTQQK LHEVKRIDGD KVVGVLADR IVTF SKTSET VDRPFGFSW
GKGTFKFVMT DLLAGTWQVL KDGKILYPAL SAKGDDGPLY FEGTEGTYRF LR

FIG.5

7/11




FIG.6

SUBSTITUTE SHEET (RULE 26)

8/11




FIG.7

9/11

ATGACTACGA AAATTTTAA AAGGATCATT GTATTGCTG TAATTGCCCT	50
ATCGTCGGGA AATATACTTG CACAAAGCTC TTCCATTACC AGGAAAGATT	100
TTGACCACAT CAACCTTGAG TATTCCGGAC TGAAAAGGT TAATAAAGCA	150
GTTGCTGCCG GCAACTATGA CGATGGGGCC AAAGCATTAC TGGCATACTA	200
CAGGGAAAAA ACTAAGGCCA GGGAACCTGA TTTCACTAAT GCAGAAAAGC	250
CTGCCGATAT ACGCCAGCCC ATAGATAAGG TTACCGTGA AATGGCCGAC	300
AAGGCTTGG TCCACCAGTT TCAACCGCAC AAAGGCTACG GCTATTTGA	350
TTATGGTAAA GACATCAACT GCCAGATGTG CCCGGTAAAA GACAATGAAG	400
TACCGCTGCA GTTGCACCGT GTAAAATGGT GGCAAGCTAT GGCCCTGGTT	450
TATCACGCTA CGGGCGATGA AAAATATGCA AGAGAATGGG TATATCAGTA	500
CAGCGATTGG GCCAGAAAAA ACCCATGGG CCTGTCGCAG GATAATGATA	550
AATTTGTGTG GCGGCCCTT GAACTGTGG ACAGGGTACA AAGTCTTCCC	600
CCAACCTTCA GCTTATTGT AACTCGCCA CCCTTACCC CAGCCTTTT	650
AATGGAATT TTAAACAGTT ACCACCAACA GGCGATTAT TTATCTACGC	700
ATTATGCCGA ACAGGGAAAC CACCGTTAT TTGAAGCCCA ACGCAACTTG	750
TTTCCAGGGC TATCTTCCC TGAATTAAA GATTACCAA GATGGAGGCA	800
AACCGGCATA TCGGTGCTGA ACACCGAGAT CAAAAAACAG GTTATGCCG	850
ATGGGATGCA GTTGAACTT TCACCAATT ACCATGTAGC TGCCATCGAT	900
ATCTTCTTAA AGGCCTATGG TTCTGAAAA CGAGTTAACC TTGAAAAAGA	950
ATTCCGCAA TCTTATGTAC AACTGTAGA AAATATGATT ATGGCGCTGA	1000

FIG.8A

SUBSTITUTE SHEET (RULE 26)

10/11

TCAGTATTTC ACTGCCAGAT TATAACACCC CTATGTTGC AGATTCA	1050
ATTACAGATA AAAATTCAG GATGGCACAG TTTCCCAGCT GGGCCCCGGT	1100
TTTCCCAGCA AACCAGGCCA TAAAATATT TGCTACAGAT GGCAAACAAG	1150
GTAAGGGGCC TAACTTTTA TCCAAAGCAT TGAGCAATGC AGCCTTTAT	1200
ACGTTAGAA CGCGATGCCA TAAAAATGCA ACCGTTATGC TATTAAGG	1250
CAGTCCTCCC GGAGAATTTC ATGCCAGCC GGATAACGGG ACTTTGAAC	1300
TTTTATAAA GGGCAGAAC TTTACCCAG ACGCCGGGT ATTGTGTAT	1350
AGCGGCGACG AAGCCATCAT GAAACTGCGG AACTGGTACC GTCAAACCG	1400
CATACACAGC ACCCTTACAC TCCACAATCA AAATATGTC ATTACAAAG	1450
CCCGGCAAAA CAAATGGAA ACAGGAAATA ACCTTGATGT GCTTACCTAT	1500
ACCAACCCAA CCTATCCGAA TCTGGACCAT CAGCGCAGTG TACTTTCAT	1550
CAACAAAAAA TACTTCTGG TCATCGATAG GGCAATAGGC GAAGCTACCG	1600
GAAACCTGGG CGTACACTGG CAGCTAAAG AAGACAGCAA CCCTGTTTC	1650
GATAAGACAA AGAACCGGT TTACACCACT TACAGAGATG GTAACAACCT	1700
GATGATCCAA TCGTTGAATG CGGACAGGAC CAGCCTCAAT GAAGAAGAAG	1750
GAAAGGTATC TTATGTTAC AATAAGGAGC TGAAAAGACC TGCTTCGTA	1800
TTGAAAAGC CTAAAAGAA TGCCGGCACA CAAAATTTG TCAGTATAGT	1850
TTATCCATAC GACGGCCAGA AGGCTCCAGA GATCAGCATA CGGGAAAACA	1900
AGGGCAATGA TTTGAGAAA GGCAAGCTTA ATCTAACCCCT TACCATTAAAC	1950
GGAAAACAAC AGCTTGTGTT GGTTCCCTAG	1980

FIG.8B

11/11

MTTKIFKRII VFAVIALSSG NILAQSSSIT RKDFDHINLE YSGLEKVNA VAAGNYDDAA

KALVHMFWPH KCYCYFDYCK
 KALLAYYREK SKAREPDFSN AEKPADIQRP IDKVREMAD KALVHQFQPH KGCGYFDYCK
PEPTIDE 3C

DIN LIK -NEVRWQLHR VK
 DINWQMMVPVK DNEVRWQLHR VKWWQAMALV YHATGDEKYA REWVYQYSDW ARKNPLGLSQ
PEPTIDE 3A

DNDKFWRPL EVSDRVQSLP PTFSLFVNSP AFTPAFLMEF LNSYHQQADY LSTHYAEQGN
 HRLFEAQRLN FAGVSFPEFK DSPRWRQTGI SVLNTEIKKQ VYADGMQFEL SPIYHVAID
 IFLKAYGSAK RVNLEKEFPQ SYVQTVENMI MALISISLPD YNTPMFGDSW ITDKNFRMAQ

VLKASPP
 FASWARVFPA NQAIFYFATD GKQGKAPNFL SKALSAGFY TFRSGWDKNA TVMVLKASPP

GEFHQAQPDNG TFELFI
 GEFHQAQPDNG TFELFIKGRN FTPDAGVFVY SGDEAIMKLR NWYRQTRIHS TLTLDNQNMV
PEPTIDE 3B

ITKARQNWKWE TGNNLDVLTY TNPSYPNLDH QRSVLFINKK YFLVIDRAIG EATGNLGVHW
 QLKEDSNPVF DKTKNRVYTT YRDGNNLMIQ SLNADRTSLN EEEGKVSYVY NKELKRPASF
 FEKPKKNACT QNFVSVVYPY DGQKAPEISI RENKGNDFEK GKLNLTLTIN GKQQLVLVP

FIG.9

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT 5/07391

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 1/21, 9/88, 15/63, 15/60, 15/09, 15/67, 15/70

US CL :435/172.3, 232, 252.3, 252.33, 320.1; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/172.3, 232, 252.3, 252.33, 320.1; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---	WO, A, 94/12618 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 09 June 1994, see entire document.	13-16 -----
Y ---	JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 267, No. 34, issued 05 December 1992, Lohse et al., "Purification and Characterization of Heparin Lyases From Flavobacterium heparinum", pages 24347-24355, see entire document.	1-12, 17-23, 32 -----
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, Volume 90, issued April 1993, Sasisekharan et al., "Cloning and Expression of Heparinase I Gene From Flavobacterium heparinum", pages 3660-3664, see entire document.	13-16 ----- 1-12, 17-23, 32 1-12, 17-23

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

31 AUGUST 1995

Date of mailing of the international search report

05 OCT 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer
Rebecca Prouty
REBECCA PROUTY

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

INTERNATION

SEARCH REPORT

In. ional application No.

PCT/US95/07391

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO, A, 93/08289 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 29 April 1993, see entire document.	1-12, 17-23
Y	APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Volume 56, No. 11, issued November 1990, Zimmermann et al., "Specific Plate Assay for Bacterial Heparinase", pages 3593-3594. see entire document.	1-12, 17-23

Form PCT/ISA/210 (continuation of second sheet)(July 1992)★

INTERNATIONAL SEARCH REPORT

International application No.
PCT JS95/07391

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1-23 and 32

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, BIOSIS, LIFESCI, EMBASE, CAS, WPI, BIOTECHDS
search terms: heparinase# or heparin lyase# or heparitinase# or heparanase# or heparan sulfate lyase#, purif? or isolat?,
flavobacterium heparinum, gene# or sequence#

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-12 and 17-23, drawn to DNA, vectors, host cells and expression of *Flavobacterium heparinum* heparinase.

Group II, claims 13-16 and 32, drawn to *Flavobacterium heparinum* heparinase.

Group III, claims 25-31, drawn to *Flavobacterium heparinum* heparinase antibodies.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The proteins of Groups I and III and the DNA of Group II are structurally distinct compounds. The proteins of Group I and III comprise unrelated amino acid sequences and the DNA of Group II comprises a nucleic acid sequence.